<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aclidinium bromide for stable chronic obstructive pulmonary disease - Ni, H - 2014 | Cochrane Library</title> <meta content="Aclidinium bromide for stable chronic obstructive pulmonary disease - Ni, H - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010509.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aclidinium bromide for stable chronic obstructive pulmonary disease - Ni, H - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010509.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010509.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Aclidinium bromide for stable chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Han Ni" name="citation_author"/> <meta content="SEGi University" name="citation_author_institution"/> <meta content="hanni.dr@gmail.com" name="citation_author_email"/> <meta content="Zay Soe" name="citation_author"/> <meta content="UCSI University" name="citation_author_institution"/> <meta content="Soe Moe" name="citation_author"/> <meta content="Faculty of Medicine, Melaka‐Manipal Medical College" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD010509.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/09/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010509.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010509.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010509.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐2 Receptor Agonists [therapeutic use]; Bronchodilator Agents [*therapeutic use]; Disease Progression; Muscarinic Antagonists [*therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Randomized Controlled Trials as Topic; Scopolamine Derivatives [therapeutic use]; Tiotropium Bromide; Tropanes [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010509.pub2&amp;doi=10.1002/14651858.CD010509.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010509\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010509\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010509.pub2",title:"Aclidinium bromide for stable chronic obstructive pulmonary disease",firstPublishedDate:"Sep 19, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010509.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010509.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010509.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010509.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010509.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010509.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010509.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010509.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010509.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010509.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2538 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010509.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/appendices#CD010509-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/table_n/CD010509StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/table_n/CD010509StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aclidinium bromide for stable chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information#CD010509-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Han Ni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information#CD010509-cr-0003">Zay Soe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information#CD010509-cr-0004">Soe Moe</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information/en#CD010509-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 September 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010509.pub2">https://doi.org/10.1002/14651858.CD010509.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010509-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010509-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010509-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010509-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010509-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010509-abs-0001" lang="en"> <section id="CD010509-sec-0001"> <h3 class="title" id="CD010509-sec-0001">Background</h3> <p>Bronchodilators are the mainstay for symptom relief in the management of stable chronic obstructive pulmonary disease (COPD). Aclidinium bromide is a new long‐acting muscarinic antagonist (LAMA) that differs from tiotropium by its higher selectivity for M3 muscarinic receptors with a faster onset of action. However, the duration of action of aclidinium is shorter than for tiotropium. It has been approved as maintenance therapy for stable, moderate to severe COPD, but its efficacy and safety in the management of COPD is uncertain compared to other bronchodilators. </p> </section> <section id="CD010509-sec-0002"> <h3 class="title" id="CD010509-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of aclidinium bromide in stable COPD.</p> </section> <section id="CD010509-sec-0003"> <h3 class="title" id="CD010509-sec-0003">Search methods</h3> <p>We identified randomised controlled trials (RCT) from the Cochrane Airways Group Specialised Register of trials (CAGR), as well as www.clinicaltrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), US Food and Drug Administration (FDA) website and Almirall Clinical Trials Registry and Results. We contacted Forest Laboratories for any unpublished trials and checked the reference lists of identified articles for additional information. The last search was performed on 7 April 2014 for CAGR and 11 April 2014 for other sources. </p> </section> <section id="CD010509-sec-0004"> <h3 class="title" id="CD010509-sec-0004">Selection criteria</h3> <p>Parallel‐group RCTs of aclidinium bromide compared with placebo, long‐acting beta<sub>2</sub>‐agonists (LABA) or LAMA in adults with stable COPD. </p> </section> <section id="CD010509-sec-0005"> <h3 class="title" id="CD010509-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed the risk of bias, and extracted data. We sought missing data from the trial authors as well as manufacturers of aclidinium. We used odds ratios (OR) for dichotomous data and mean difference (MD) for continuous data, and reported both with their 95% confidence intervals (CI). We used standard methodological procedures expected by The Cochrane Collaboration. We applied the GRADE approach to summarise results and to assess the overall quality of evidence. </p> </section> <section id="CD010509-sec-0006"> <h3 class="title" id="CD010509-sec-0006">Main results</h3> <p>This review included 12 multicentre RCTs randomly assigning 9547 participants with stable COPD. All the studies were industry‐sponsored and had similar inclusion criteria with relatively good methodological quality. All but one study included in the meta‐analysis were double‐blind and scored low risk of bias. The study duration ranged from four weeks to 52 weeks. Participants were more often males, mainly Caucasians, mean age ranging from 61.7 to 65.6 years, and with a smoking history of 10 or more pack years. They had moderate to severe symptoms at randomisation; the mean post‐bronchodilator forced expiratory volume in one second (FEV1) was between 46% and 57.6% of the predicted normal value, and the mean St George's Respiratory Questionnaire score (SGRQ) ranged from 45.1 to 50.4 when reported. </p> <p>There was no difference between aclidinium and placebo in all‐cause mortality (low quality) and number of patients with exacerbations requiring a short course of oral steroids or antibiotics, or both (moderate quality). Aclidinium improved quality of life by lowering the SGRQ total score with a mean difference of ‐2.34 (95% CI ‐3.18 to ‐1.51; I<sup>2</sup> = 48%, 7 trials, 4442 participants) when compared to placebo. More patients on aclidinium achieved a clinically meaningful improvement of at least four units decrease in SGRQ total score (OR 1.49; 95% CI 1.31 to 1.70; I<sup>2</sup> = 34%; number needed to treat (NNT) = 10, 95% CI 8 to 15, high quality evidence) over 12 to 52 weeks than on placebo. Aclidinium also resulted in a significantly greater improvement in pre‐dose FEV1 than placebo with a mean difference of 0.09 L (95% CI 0.08 to 0.10; I<sup>2</sup> = 39%, 9 trials, 4963 participants). No trials assessed functional capacity. Aclidinium reduced the number of patients with exacerbations requiring hospitalisation by 4 to 20 fewer per 1000 over 4 to 52 weeks (OR 0.64; 95% CI 0.46 to 0.88; I<sup>2</sup> = 0%, 10 trials, 5624 people; NNT = 77, 95% CI 51 to 233, high quality evidence) compared to placebo. There was no difference in non‐fatal serious adverse events (moderate quality evidence) between aclidinium and placebo. </p> <p>Compared to tiotropium, aclidinium did not demonstrate significant differences for exacerbations requiring oral steroids or antibiotics, or both, exacerbation‐related hospitalisations and non‐fatal serious adverse events (very low quality evidence). Inadequate data prevented the comparison of aclidinium to formoterol or other LABAs. </p> </section> <section id="CD010509-sec-0007"> <h3 class="title" id="CD010509-sec-0007">Authors' conclusions</h3> <p>Aclidinium is associated with improved quality of life and reduced hospitalisations due to severe exacerbations in patients with moderate to severe stable COPD compared to placebo. Overall, aclidinium did not significantly reduce mortality, serious adverse events or exacerbations requiring oral steroids or antibiotics, or both. </p> <p>Currently, the available data are insufficient and of very low quality in comparisons of the efficacy of aclidinium versus tiotropium. The efficacy of aclidinium versus LABAs cannot be assessed due to inaccurate data. Thus additional trials are recommended to assess the efficacy and safety of aclidinium compared to other LAMAs or LABAs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010509-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010509-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010509-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010509-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010509-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010509-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010509-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010509-abs-0002" lang="en"> <h3>Effectiveness and safety of inhalers containing the drug aclidinium bromide for managing patients with stable COPD </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on the effectiveness and safety of aclidinium inhalers used by people with chronic obstructive pulmonary disease (COPD). </p> <p><b>Background</b> </p> <p>COPD, also known as 'smoker's lung disease', includes conditions called emphysema and chronic bronchitis where there is airway narrowing that cannot be fully corrected. It is a progressive disease. COPD patients usually have breathing problems and a cough that produces a lot of phlegm. It is diagnosed by international guidelines set by the Global Initiative for Obstructive Lung Disease (GOLD). Symptoms may worsen during flare‐ups. The main aims of treating COPD patients are to relieve symptoms, reduce flare‐ups and improve quality of life. Aclidinium is a new inhaled drug that widens the airways (a bronchodilator). It is delivered by an inhaler called Genuair or Pressair. We wanted to discover whether aclidinium was better or worse than using other inhalers or a dummy inhaler. </p> <p><b>Study characteristics</b> </p> <p>The evidence was current to 7 April 2014. We included 12 studies involving 9547 COPD patients over a period of four to 52 weeks. These studies were sponsored by drug companies and were well designed. Both patients and the people doing the research did not know which treatment the patients were getting; although in one study one treatment was known to both parties. More men than women took part, and they were mostly Caucasians. They were in their 60s and had smoked a lot in their lives. These people had moderate to severe symptoms when they started treatment. </p> <p><b>Key results</b> </p> <p>Aclidinium did not reduce the number of people with flare‐ups that need additional drugs. There was little or no difference in deaths or serious side effects between aclidinium and a dummy inhaler. Aclidinium inhalers improved quality of life more than the dummy inhalers. </p> <p>People who took aclidinium had fewer hospital admissions due to serious flare‐ups. Based on our results, among 1000 COPD patients using a dummy inhaler over four weeks to one year 37 would have severe flare‐ups needing hospital admission. Only 17 to 33 patients out of 1000 would require hospital admission if they were using aclidinium inhalers. We also set out to compare this new medication with tiotropium, which is already used to treat COPD. There were only two studies for this comparison thus we could not be sure how aclidinium compared to tiotropium. We also could not compare aclidinium with another well known inhaler that contains the drug formoterol because of unreliable data. </p> <p><b>Quality of the evidence</b> </p> <p>For the comparison of aclidinium inhalers and dummy inhalers, we are confident that there are benefits in terms of the number of hospitalisations and patients' quality of life; we are less certain about the numbers of flare‐ups needing additional drugs and serious side effects. We do not have enough information to assess any effect on the number of deaths. We did not have enough information to reliably compare aclidinium with tiotropium or formoterol. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010509-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010509-sec-0096"></div> <h3 class="title" id="CD010509-sec-0097">Implications for practice</h3> <section id="CD010509-sec-0097"> <p>Inhaled aclidinium bromide use in stable COPD is associated with better health‐related quality of life and fewer hospitalisations due to severe exacerbations than with placebo. The results from this review indicate a larger percentage of patients attaining the minimal clinically important difference of at least four units change and a small mean improvement in health‐related quality of life for patients on aclidinium therapy compared to placebo. Aclidinium does not significantly lower the number of patients with exacerbations requiring a short course of oral steroids or antibiotics or both compared to placebo. Significant improvements in spirometric indices of trough and peak FEV1, and trough and peak FVC were seen with aclidinium compared with placebo. Adverse events, non‐fatal serious adverse events and mortality did not differ significantly between aclidinium and placebo. Currently available data for aclidinium in comparison to tiotropium were insufficient for coming to a valid conclusion. Inappropriate drug delivery of formoterol limits our effort to determine the relative efficacy and safety of aclidinium compared to LABAs. We did not conduct a cost‐effectiveness analysis so we cannot comment on implications for resource allocations. </p> </section> <h3 class="title" id="CD010509-sec-0098">Implications for research</h3> <section id="CD010509-sec-0098"> <p>Additional long‐term studies are required to establish the risks and benefits of aclidinium compared to LAMAs and LABAs. Pharmacoeconomic analyses would be helpful to assist healthcare providers in making decisions about the cost‐effectiveness of aclidinium compared to other long‐acting bronchodilators such as LABA and LAMA. In future COPD trials, strategies using specific approved inhalers for formoterol, tiotropium and aclidinium while maintaining the procedure of blinding should be implemented to have accurate data for the individual interventions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010509-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010509-sec-0022"></div> <div class="table" id="CD010509-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with stable chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> aclidinium bromide<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Aclidinium bromide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause)</b> <br/> Follow‐up: 6‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (2 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b> <br/> (0.43 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5252<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids, antibiotics or both</b> <br/> Follow‐up: 4‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b> <br/> (105 to 141) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b> <br/> (0.74 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5624<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> <br/> Number of patients who achieved at least 4 units improvement in SGRQ total score<br/> Follow‐up: 12‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>396 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>494 per 1000</b> <br/> (462 to 527) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.49</b> <br/> (1.31 to 1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4420<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life (SGRQ total score change from baseline) in the intervention groups was 2.34 lower (3.18 to 1.51 lower); (4442 participants; 7 studies) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional capacity</b> <br/> Six‐minute walking distance </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study assessed functional capacity</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations</b> <br/> Follow‐up: 4‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (17 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.64</b> <br/> (0.46 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5624<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b> <br/> Follow‐up: 4‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (40 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> <br/> (0.7 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5651<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> ‐2 for imprecision: the CI includes the possibility of both appreciable benefit and harm.<br/> <sup>2</sup><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> failed to report some outcomes of lung function in the published full text but it is unlikely to affect this outcome.<br/> <sup>3</sup><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> is double blinded for aclidinium and placebo arms though it is open label for tiotropium arm with no study limitation for this comparison.<br/> <sup>4</sup> ‐1 for imprecision: the CI includes important benefit and potential harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010509-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with stable chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> aclidinium bromide<br/> <b>Comparison:</b> tiotropium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tiotropium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Aclidinium bromide </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329<br/> (1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids, antibiotics or both</b> <br/> Follow‐up: 4‐6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (0 to 26)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.64</b> <br/> (0.31 to 22.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> <br/> St George's Respiratory Questionnaire (SGRQ) score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies measured and reported quality of life for aclidinium and tiotropium</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional capacity</b> <br/> Six‐minute walk distance </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies measured and reported functional capacity for aclidinium and tiotropium</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations</b> <br/> Follow‐up: 4‐6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (0 to 18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b> <br/> (0.07 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b> <br/> Follow‐up: 4‐6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (3 to 46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.67</b> <br/> (0.17 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The corresponding risk for aclidinium bromide was calculated using the risk difference to avoid having zero in both columns. </p> <p><sup>2</sup> ‐1 for high risk of bias in <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> because it was open label for tiotropium arm.<br/> <sup>3</sup><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> failed to report some outcomes of lung function in the published full text but it is unlikely to affect this outcome.<br/> <sup>4</sup> ‐2 for imprecision: the CI includes the possibility of both appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010509-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010509-sec-0023"></div> <section id="CD010509-sec-0024"> <h3 class="title" id="CD010509-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is "a common, preventable and treatable disease, characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases" (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). Tobacco smoke is the major risk factor in the pathogenesis of COPD; chemicals, occupational exposures, indoor and outdoor air pollution are also recognised risk factors (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>; <a href="./references#CD010509-bbs2-0064" title="HoggJC , TimensW . The pathology of chronic obstructive pulmonary disease. Annual Review of Pathology: Mechanisms of Disease2009;4:435‐59. ">Hogg 2009</a>; <a href="./references#CD010509-bbs2-0073" title="MacNeeW . ABC of chronic obstructive pulmonary disease: pathology, pathogenesis, and pathophysiology. BMJ2006;332:1202‐4. ">MacNee 2006</a>; <a href="./references#CD010509-bbs2-0086" title="AbramsonM , CrockettAJ , DabscheckE , FrithPA , GeorgeJ , GlasgowN , et al. on behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. The COPD‐X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.35 2013. http://www.copdx.org.au/ (accessed 14 February 2014). ">TSANZ 2012</a>; <a href="./references#CD010509-bbs2-0094" title="World Health Organization. Chronic obstructive pulmonary disease. http://www.who.int/respiratory/copd/en (accessed 25 December 2012). ">WHO 2012</a>). </p> <p>COPD is the third leading cause of death after heart disease and malignancy in the United States (<a href="./references#CD010509-bbs2-0054" title="HoyertDL , XuJ . Deaths: preliminary data for 2011 (National Vital Statistics Reports). http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf (accessed 25 December 2012). ">CDC 2011</a>) and accounts for approximately 30,000 deaths each year in the UK (<a href="./references#CD010509-bbs2-0076" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. http://guidance.nice.org.uk/CG101/Guidance/pdf/English (accessed 25 December 2012). ">NICE 2010</a>). It was the fourth leading cause of mortality in 2004, with three million deaths worldwide (<a href="./references#CD010509-bbs2-0092" title="World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (accessed 25 December 2012). ">WHO 2008</a>). Ninety per cent of deaths from COPD occurred in low and middle‐income countries in 2008 (<a href="./references#CD010509-bbs2-0093" title="World Health Organization. Global status report on noncommunicable diseases 2010. http://www.who.int/nmh/publications/ncd_report2010/en/ (accessed 25 December 2012). ">WHO 2010</a>). The World Health Organization (WHO) has estimated that COPD will become the third leading cause of death worldwide in 2030 due to a projected increase in smoking and environmental pollution (<a href="./references#CD010509-bbs2-0095" title="World Health Organization. COPD predicted to be third leading cause of death in 2030. http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/index.html# (accessed 25 December 2012). ">WHO 2012a</a>). Exacerbations and co‐morbidities contribute to the overall severity of COPD in patients (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). Currently available prevalence data do not reflect the actual total burden of COPD because of under reporting, with diagnosis only being made when the disease is clinically apparent (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). </p> <p>COPD also has a significant economic impact, mainly due to exacerbations. The total annual cost of COPD to the National Health Service (NHS) in the UK is estimated to be over GBP 800 million, for direct healthcare costs (<a href="./references#CD010509-bbs2-0077" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 25 December 2012). ">NICE 2011</a>). It accounts for 56% (EUR 38.6 billion) of the total cost of respiratory diseases in the European Union, while the estimated cost in the United States (US) is USD 29.5 billion and USD 20.4 billion, for direct and indirect costs respectively (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). </p> <p>Acute exacerbations are a major cause of morbidity and mortality in COPD patients and are defined as "an event in the natural course of the disease characterised by a change in the patient's baseline dyspnoea, cough, and/or sputum, that is beyond normal day‐to‐day variations, is acute in onset and may warrant a change in medication in a patient with underlying COPD" (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). </p> <p>Currently there is no cure for COPD. Apart from smoking cessation and long‐term oxygen therapy in severely hypoxic patients, other therapeutic options do not improve survival (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). Thus, the major goal of medication is to relieve symptoms, reduce the frequency and severity of exacerbations, and improve quality of life (<a href="./references#CD010509-bbs2-0053" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">ATS/ERS 2011</a>; <a href="./references#CD010509-bbs2-0056" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2] ">Chong 2012</a>; <a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>; <a href="./references#CD010509-bbs2-0084" title="SutherlandER , CherniackRM . Management of chronic obstructive pulmonary disease. New England Journal of Medicine2004;350(26):2689‐97. [PUBMED: 15215485] ">Sutherland 2004</a>; <a href="./references#CD010509-bbs2-0086" title="AbramsonM , CrockettAJ , DabscheckE , FrithPA , GeorgeJ , GlasgowN , et al. on behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. The COPD‐X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.35 2013. http://www.copdx.org.au/ (accessed 14 February 2014). ">TSANZ 2012</a>). </p> <p>Management of stable COPD is multidisciplinary, with options such as smoking cessation (<a href="./references#CD010509-bbs2-0087" title="van derMeerRM , WagenaE , OsteloRWJG , JacobsAJE , vanSchayckCP . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD002999] ">van der Meer 2012</a>); education (<a href="./references#CD010509-bbs2-0058" title="EffingT , MonninkhofEEM , van derValkPPDLPM , ZielhuisGGA , WaltersEH , van derPalenJJ , et al. Self‐management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2] ">Effing 2009</a>); vaccination for influenza (<a href="./references#CD010509-bbs2-0078" title="PooleP , ChackoEE , Wood‐BakerR , CatesCJ . Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD002733.pub2] ">Poole 2010</a>) and pneumococcal infections (<a href="./references#CD010509-bbs2-0090" title="WaltersJAE , SmithS , PooleP , GrangerRH , Wood‐BakerR . Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD001390.pub2] ">Walters 2010</a>); breathing exercises (<a href="./references#CD010509-bbs2-0065" title="HollandAE , HillCJ , JonesAY , McDonaldCF . Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD008250.pub2] ">Holland 2012</a>); pulmonary rehabilitation (<a href="./references#CD010509-bbs2-0072" title="LacasseY , GoldsteinR , LassersonTJ , MartinS . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003793.pub2] ">Lacasse 2009</a>); pharmacotherapy with inhaled bronchodilators, inhaled corticosteroids for severe COPD or frequent exacerbations (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>; <a href="./references#CD010509-bbs2-0086" title="AbramsonM , CrockettAJ , DabscheckE , FrithPA , GeorgeJ , GlasgowN , et al. on behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. The COPD‐X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.35 2013. http://www.copdx.org.au/ (accessed 14 February 2014). ">TSANZ 2012</a>; <a href="./references#CD010509-bbs2-0098" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>), phosphodiesterase‐4 inhibitors (<a href="./references#CD010509-bbs2-0055" title="ChongJ , PooleP , LeungB , BlackPN . Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD002309.pub2] ">Chong 2011</a>); long‐term domiciliary oxygen therapy (<a href="./references#CD010509-bbs2-0057" title="CranstonJM , CrockettA , MossJ , AlpersJH . Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD001744.pub2] ">Cranston 2008</a>); and lung volume reduction surgery (<a href="./references#CD010509-bbs2-0085" title="TiongLU , GibsonPG , HensleyMJ , HepworthR , LassersonTJ , SmithB , et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD001001.pub2] ">Tiong 2009</a>). Regular long‐term use of oral corticosteroids is not recommended for stable COPD and is associated with an increased risk of systemic side effects (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>; <a href="./references#CD010509-bbs2-0089" title="WaltersJAE , WaltersEH , Wood‐BakerR . Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD005374] ">Walters 2009</a>). Oral theophylline has a modest bronchodilator effect (<a href="./references#CD010509-bbs2-0080" title="RamFSF , JonesP , JardimJ , CastroAA , AtallahÁN , LacasseY , et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD003902] ">Ram 2009</a>) but is less effective than inhaled long‐acting bronchodilators (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). Mucolytic agents show a slight reduction in exacerbations but have no effect on the overall quality of life (<a href="./references#CD010509-bbs2-0079" title="PooleP , BlackPN , CatesCJ . Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD001287.pub4] ">Poole 2012</a>). Neither of these medications are routinely recommended for stable COPD (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>). Long‐acting bronchodilators, either a long‐acting beta<sub>2</sub>‐agonist (LABA) (<a href="./references#CD010509-bbs2-0075" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD010509-bbs2-0091" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD007891.pub2] ">Welsh 2011</a>) or a long‐acting muscarinic antagonist (LAMA) (<a href="./references#CD010509-bbs2-0071" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009285.pub2] ">Karner 2012</a>), are the first‐line maintenance therapy for moderate to severe, stable COPD (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>; <a href="./references#CD010509-bbs2-0076" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. http://guidance.nice.org.uk/CG101/Guidance/pdf/English (accessed 25 December 2012). ">NICE 2010</a>). </p> </section> <section id="CD010509-sec-0025"> <h3 class="title" id="CD010509-sec-0025">Description of the intervention</h3> <p>Aclidinium bromide is a new long‐acting antimuscarinic agent that blocks the action of the neurotransmitter acetylcholine. It was approved by the US Food and Drug Administration (FDA) on 23 July 2012 for use in moderate to severe, stable COPD patients (<a href="./references#CD010509-bbs2-0059" title="United StatesFood , Drug Administration(FDA) . Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000TOC.cfm (accessed 25 December 2012). ">FDA 2012</a>). It is marketed as Tudorza Pressair by Forest Laboratories and <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a> in the US. It is a dry powder formulation (<a href="./references#CD010509-bbs2-0082" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. [PUBMED: 22003291] ">Sims 2011</a>) and the FDA approved dosage is 400 µg inhaled twice daily. In Europe and the UK it has been launched as Eklira Genuair by <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>. </p> <p>It is delivered by a state of the art multidose dry powder inhaler (MDPI), termed Genuair or Pressair, which is preloaded with a one‐month supply of medication. The MDPI is specially designed with a visible dose level indicator with an anti‐double dosing mechanism, multiple feedback mechanisms to indicate successful inhalation, such as an audible click and a slightly sweet taste, as well as an end‐of‐dose lock‐out system to prevent further use after the final dose (<a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>; <a href="./references#CD010509-bbs2-0082" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. [PUBMED: 22003291] ">Sims 2011</a>). </p> </section> <section id="CD010509-sec-0026"> <h3 class="title" id="CD010509-sec-0026">How the intervention might work</h3> <p>Airway obstruction mediated by vagal cholinergic tone is the major reversible contributor to COPD (<a href="./references#CD010509-bbs2-0066" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098801/ (accessed 25 December 2012). [DOI: 10.1186/1465‐9921‐12‐55] ">Jones 2011</a>). Currently there are five known subtypes of muscarinic cholinergic receptors (M1 to M5), of which three (M1, M2 and M3) are present in the bronchial airway smooth muscle (<a href="./references#CD010509-bbs2-0070" title="KarakiulakisG , RothM . Muscarinic receptors and their antagonists in COPD: anti‐inflammatory and anti‐remodeling effects. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512336/ (accessed 25 December 2012). [DOI: 10.1155/2012/409580] ">Karakiulakis 2012</a>; <a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>). </p> <p>Acetylcholine acts on M1 receptors to facilitate further neurotransmission from parasympathetic ganglia, and binds to M3 receptors located on the airway smooth muscle cells to induce bronchoconstriction. M2 receptors mediate feedback inhibition of acetylcholine release at the cholinergic nerve endings (<a href="./references#CD010509-bbs2-0070" title="KarakiulakisG , RothM . Muscarinic receptors and their antagonists in COPD: anti‐inflammatory and anti‐remodeling effects. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512336/ (accessed 25 December 2012). [DOI: 10.1155/2012/409580] ">Karakiulakis 2012</a>; <a href="./references#CD010509-bbs2-0082" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. [PUBMED: 22003291] ">Sims 2011</a>; <a href="./references#CD010509-bbs2-0088" title="VogelmeierC , BanerjiD . NVA237, a long‐acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2011;5(3):163‐73. [PUBMED: 21511677] ">Vogelmeier 2011</a>). </p> <p>Aclidinium bromide is a LAMA which inhibits the action of acetylcholine at the muscarinic receptors with approximately a six‐fold kinetic selectivity for M3 receptors compared to the M2 subtype, resulting in a more effective bronchodilator action with fewer M2 mediated cardiac side effects (<a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>; <a href="./references#CD010509-bbs2-0082" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. [PUBMED: 22003291] ">Sims 2011</a>). The onset of action of aclidinium bromide (30 minutes) is similar to ipratropium (30 minutes) but faster than tiotropium (80 minutes). The duration of action of aclidinium (t<sub>1/2</sub> = 29 hours) is shorter than for tiotropium (t<sub>1/2</sub> = 64 hours) but longer than for ipratropium (t<sub>1/2</sub> = 8 hours) (<a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>). </p> <p>These muscarinic receptors are also present in other parts of the body, such as M1 receptors in the central nervous system (CNS); M2 in the heart; M3 in the gastrointestinal tract (GIT), iris and sphincter; and M4 in the neostriatum, whereas the functional role of M5 receptors is unclear (<a href="./references#CD010509-bbs2-0061" title="GavaldàA , Garcia‐GilE . Aclidinium bromide, a novel long‐acting muscarinic antagonist (LAMA). New drugs and targets for asthma and COPD. Progress in Respiratory Research2010;39:33‐8. ">Gavaldà 2010</a>). Thus, the non‐selective blockade of muscarinic receptors has the potential for systemic side effects. </p> <p>Aclidinium has been shown in preclinical and clinical studies to rapidly hydrolyse in the plasma into two inactive metabolites, with a very short plasma half life of 2.4 minutes, while the plasma half life for ipratropium is 96 minutes and for tiotropium it is more than six hours (<a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>). This low and transient level in the plasma leads to less drug‐drug interaction and contributes to a more favourable safety profile. </p> </section> <section id="CD010509-sec-0027"> <h3 class="title" id="CD010509-sec-0027">Why it is important to do this review</h3> <p>Although a long‐lasting bronchodilator effect and favourable safety profile of aclidinium bromide has been shown in a number of clinical trials (<a href="./references#CD010509-bbs2-0066" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098801/ (accessed 25 December 2012). [DOI: 10.1186/1465‐9921‐12‐55] ">Jones 2011</a>; <a href="./references#CD010509-bbs2-0067" title="JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] ">Jones 2012</a>), the summarised safety and efficacy profile of this agent is lacking when compared to placebo or currently established treatment options such as LABAs or LAMAs. We aimed to fill this gap by performing a systematic review of the findings of all available randomised controlled trials to help clinicians provide evidence‐based, long‐term management of stable COPD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010509-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010509-sec-0028"></div> <p>To assess the efficacy and safety of aclidinium bromide in stable COPD.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010509-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010509-sec-0029"></div> <section id="CD010509-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010509-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with a parallel‐group design comparing aclidinium bromide with placebo or a LABA or LAMA, both open‐label and blinded studies. Since COPD is a progressive disorder which deteriorates with time, we excluded cross‐over trials. We also excluded cluster‐randomised trials to avoid bias. </p> </section> <section id="CD010509-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies involving adults (over 18 years of age) diagnosed with moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (<a href="./references#CD010509-bbs2-0062" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 14 February 2013). ">GOLD 2013</a>), American Thoracic Society (ATS), European Respiratory Society (ERS) (<a href="./references#CD010509-bbs2-0053" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">ATS/ERS 2011</a>), Thoracic Society of Australia and New Zealand (<a href="./references#CD010509-bbs2-0086" title="AbramsonM , CrockettAJ , DabscheckE , FrithPA , GeorgeJ , GlasgowN , et al. on behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. The COPD‐X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.35 2013. http://www.copdx.org.au/ (accessed 14 February 2014). ">TSANZ 2012</a>), UK National Institute for Health and Clinical Excellence (<a href="./references#CD010509-bbs2-0076" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. http://guidance.nice.org.uk/CG101/Guidance/pdf/English (accessed 25 December 2012). ">NICE 2010</a>) or the WHO. Participants in the studies had evidence of airway obstruction (post‐bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of &lt; 70% and FEV1 &lt; 80% of predicted value) with clinical presentation of dyspnoea, chronic cough or sputum production with or without a history of smoking. We excluded studies which enrolled patients with bronchial asthma, bronchiectasis, cystic fibrosis or other lung diseases. </p> </section> <section id="CD010509-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD010509-list-0001"> <li> <p>Aclidinium bromide versus placebo</p> </li> <li> <p>Aclidinium bromide versus long‐acting beta<sub>2</sub>‐agonist (LABA) </p> </li> <li> <p>Aclidinium bromide versus long‐acting muscarinic antagonist (LAMA)</p> </li> </ol> </p> </section> <section id="CD010509-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010509-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010509-list-0002"> <li> <p>Mortality (all‐cause and respiratory)</p> </li> <li> <p>Exacerbations requiring a short course of an oral steroid or antibiotic, or both</p> </li> <li> <p>Quality of life measured by a validated scale, the St George's Respiratory Questionnaire (SGRQ) or Chronic Respiratory Disease Questionnaire (CRQ) </p> </li> </ol> </p> </section> <section id="CD010509-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010509-list-0003"> <li> <p>Change in lung function (FEV1, FEV1/FVC)</p> </li> <li> <p>Functional capacity by six‐minute walking distance</p> </li> <li> <p>Hospital admissions due to exacerbations or from all causes</p> </li> <li> <p>Improvement in symptoms measured by the Transitional Dyspnoea Index (TDI)</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Non‐fatal serious adverse events</p> </li> <li> <p>Withdrawals due to lack of efficacy or adverse events</p> </li> </ol> </p> <p>We assessed mortality and exacerbations as primary outcomes since exacerbations are the major cause of morbidity and mortality in COPD patients. We also classified quality of life as a primary outcome since it is one of the most important parameters that can measure both the subjective and objective well‐being of COPD patients, who have to live with this chronic disease. We recorded change in lung function from the baseline, exercise capacity, hospital admissions and symptom improvement as secondary outcomes as these may not directly reflect mortality and morbidity in COPD. For the safety profile of this new intervention (aclidinium bromide), we studied adverse events, non‐fatal serious adverse events and withdrawals from studies as secondary outcome measures. </p> </section> </section> </section> <section id="CD010509-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010509-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD010509-sec-0102">Appendix 1</a> for further details). We searched all records in the CAGR coded as 'COPD' using the following terms: </p> <p>Aclidinium* or "LAS34273" or "Tudorza" or "Eklira" or "Genuair" or "Pressair" or "LAMA" or "Muscarinic Antagonist*". </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="./appendices#CD010509-sec-0108">Appendix 2</a>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="./references#CD010509-bbs2-0096" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP) search portal. http://apps.who.int/trialsearch/ (accessed 2 May 2014). ">WHO ICTRP</a>) for additional trials. We searched all databases from their inception with no restrictions on language of publication. The initial search was conducted in March 2013 and it was updated in April 2014. </p> </section> <section id="CD010509-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We thoroughly checked the reference lists of all primary studies and review articles for additional references. We contacted corresponding authors of identified trials and asked them to identify other published and unpublished studies. We also contacted manufacturers and experts in the field. We searched the US FDA website (<a href="./references#CD010509-bbs2-0059" title="United StatesFood , Drug Administration(FDA) . Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000TOC.cfm (accessed 25 December 2012). ">FDA 2012</a>) for details of the clinical trials. In addition, we searched the manufacturers' websites (<a href="./references#CD010509-bbs2-0060" title="Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc. http://www.forestpharm.com/ (accessed 25 December 2012). ">Forest Pharmaceuticals</a> and <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>) for additional information on the studies identified through the electronic searches. We had planned to translate studies published in a language other than English. </p> </section> </section> <section id="CD010509-sec-0040"> <h3 class="title" id="CD010509-sec-0040">Data collection and analysis</h3> <section id="CD010509-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HN and SM) independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third review author (ZS) who is an expert in the field. We included the trials meeting the criteria regardless of language or publication status (published, unpublished, in press and in progress). We recorded the excluded studies together with the reasons for exclusion. </p> </section> <section id="CD010509-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HN and SM) independently extracted and recorded the data from included studies using standard data extraction forms. The data were cross‐checked. The data extraction included study characteristics: mainly study design, participants, interventions, primary and secondary outcome measures; and the analysis performed in the original studies. Where there were discrepancies, we consulted a third review author (ZS) to resolve the inconsistencies. In the case of insufficient or missing data, we contacted the corresponding authors of the studies for additional information. One of the review authors (HN) entered the data into <a href="./references#CD010509-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager 5</a> software for analysis and the data were checked by another review author (SM). </p> </section> <section id="CD010509-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HN and SM) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010509-bbs2-0063" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or by involving a third assessor (ZS). We assessed the risk of bias according to the following domains: </p> <p> <ol id="CD010509-list-0004"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear. We recorded these judgements in the 'Risk of bias' tables accompanying the characteristics of each included study and summarised them in the 'Risk of bias' summary figure. We contacted the investigators of the RCTs for the details of procedures involved in the conduct of the trials and the replies were kept for evidence. We had planned to exclude trials with high risk of bias. We used the information from the assessment of risk of bias to carry out stratified analysis. </p> </section> <section id="CD010509-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010509-sec-0045"> <h5 class="title">Dichotomous data</h5> <p>We analysed dichotomous outcome data (such as mortality, exacerbations and withdrawals) using the Mantel‐Haenszel odds ratio (OR) with 95% confidence interval (CI). We had planned to apply the Peto odds ratio if events were rare. </p> <p>We also calculated the number needed to treat (NNT) for dichotomous outcomes to reflect the number of patients necessary to obtain a beneficial or harmful outcome with the intervention. </p> </section> <section id="CD010509-sec-0046"> <h5 class="title">Continuous data</h5> <p>We assessed continuous data variables (such as quality of life, symptoms, lung function and exercise capacity) as fixed‐effect mean differences (MD) with 95% CIs when the same scale was used to measure the outcome in all the included studies. We planned to use the standardised mean difference (SMD) when all studies assessed the same outcome but measured it in different ways. We preferentially applied the MD based on change from baseline over the MD based on absolute values. </p> </section> </section> <section id="CD010509-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed the participants as the unit of analysis for dichotomous data. For continuous data we used the MD, which was the average change from baseline and not the absolute mean. For outcomes that may occur more than once, such as exacerbations, hospital admissions and adverse events, we analysed the number of participants with one or more events. </p> </section> <section id="CD010509-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the investigators or study sponsors in order to verify key study characteristics and to obtain missing numerical outcome data, where possible. In cases where missing data were not available despite attempts to obtain the data, we recorded this information in our review. We performed sensitivity analyses to assess the impact of unknown status or assumptions made about missing data on participants who withdrew from the trials on the overall pooled result of the meta‐analysis. We followed the intention‐to‐treat (ITT) principle in the analysis of outcomes from the randomised trials, if appropriate. </p> </section> <section id="CD010509-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between the trials by checking for poor overlap of the confidence intervals in the forest plot and by applying the Chi<sup>2</sup> test, with a 10% level of significance. in each analysis we used the I² statistic to measure the percentage of inconsistency in results due to inter‐trial variability. When we identified substantial heterogeneity, we explored it by pre‐specified subgroup analysis. The level of statistical variation between the trials was considered as high if the I² value was more than 50%. </p> </section> <section id="CD010509-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We minimised reporting bias as a result of non‐publication of studies or selective outcome reporting by using a systematic search strategy, contacting study authors and manufacturers, and checking multiple references of the included studies. We also visually inspected funnel plots for asymmetry. If we suspected reporting bias because of the asymmetrical appearance of the funnel plot after exclusion of other reasons for funnel plot asymmetry, we had planned to contact the study authors requesting them to provide any missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we had planned to explore the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD010509-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We analysed the data using <a href="./references#CD010509-bbs2-0081" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">Review Manager 5</a>. For pooling the outcomes of the studies, we used a fixed‐effect model if the I<sup>2</sup> statistic was consistent with homogeneous results. We applied a random‐effects model for data synthesis when heterogeneity was identified (I<sup>2</sup> &gt; 50%) and it could not be explained by factors identified in the subgroup analyses. We combined dichotomous outcome variables using a Mantel‐Haenszel OR with 95% CI. For continuous outcome data, we analysed the results as MD with 95% CI. Where treatment effects were reported as MD with 95% CI or exact P value, we had planned to calculate the standard error, enter it with the MD, and combine the results using a fixed‐effect model generic inverse variance (GIV) analysis. We calculated the NNT from the pooled OR and assumed control risk (ACR) using the formula described in Section 12.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010509-bbs2-0063" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We created summary of findings tables using the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010509-bbs2-0063" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. www.cochrane‐handbook.org. ">Higgins 2011</a>) and using the GRADEpro software for overall grading of the quality of the evidence. We included the following outcomes. </p> <p> <ol id="CD010509-list-0005"> <li> <p>Mortality (all‐cause and respiratory).</p> </li> <li> <p>Exacerbations requiring a short course of an oral steroid or antibiotic, or both.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Functional capacity by the six‐minute walking distance.</p> </li> <li> <p>Hospital admissions due to exacerbations or all causes.</p> </li> <li> <p>Non‐fatal serious adverse events.</p> </li> </ol> </p> </section> <section id="CD010509-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If there was significant heterogeneity, we had planned to perform subgroup analysis in order to explain it. We had planned to carry out the following subgroup analyses. </p> <p> <ol id="CD010509-list-0006"> <li> <p>Dose of aclidinium bromide (e.g. 200 µg; 400 µg).</p> </li> <li> <p>Frequency of aclidinium bromide (once daily; twice daily).</p> </li> <li> <p>Duration of treatment period (short‐term (12 weeks or less); long‐term (more than 12 weeks)). </p> </li> <li> <p>Disease severity at baseline (FEV1 &lt; 50% predicted; FEV1 ≥ 50% predicted).</p> </li> <li> <p>Concurrent therapy with theophylline (dichotomised as yes or no).</p> </li> </ol> </p> <p>We had planned to include the following outcomes in subgroup analyses.</p> <p> <ol id="CD010509-list-0007"> <li> <p>Exacerbations.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Change in lung function.</p> </li> </ol> </p> </section> <section id="CD010509-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of our analyses by repeating the meta‐analysis after exclusion of studies with high risk of bias and those with unclear methodological data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010509-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010509-sec-0054"></div> <section id="CD010509-sec-0055"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010509-sec-0123" title="">Characteristics of included studies</a>; <a href="./references#CD010509-sec-0124" title="">Characteristics of excluded studies</a>; <a href="./references#CD010509-sec-0125" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD010509-sec-0126" title="">Characteristics of ongoing studies</a> for complete details. </p> <section id="CD010509-sec-0056"> <h4 class="title">Results of the search</h4> <p>We conducted the initial search of the Cochrane Airways Group Specialised Register of trials (CAGR) on 14 March 2013 and the search of other sources (<a href="./references#CD010509-bbs2-0096" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP) search portal. http://apps.who.int/trialsearch/ (accessed 2 May 2014). ">WHO ICTRP</a>, <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>, www.clinicaltrials.gov) on 28 June 2013 with no restriction on language. In January 2014, a second search was done for all resources. A third updated search was conducted on 7 April 2014 for the CAGR and on 11 April 2014 for other sources. We identified a total of 189 records from the CAGR (103 from the first search, 59 from the second, and 27 from the third search) and a total of 107 reports from other sources (40 from <a href="./references#CD010509-bbs2-0096" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP) search portal. http://apps.who.int/trialsearch/ (accessed 2 May 2014). ">WHO ICTRP</a>, 38 from www.clinicaltrials.gov, 24 from <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a> clinical trial registry, five from the reference lists of included studies). After removal of duplicates, we screened the titles and abstracts of 240 records for eligibility and excluded 106 reports. We thoroughly studied the remaining 134 references for further assessment, retrieving full text articles where applicable and contacting manufacturers about unpublished trials. From our search, we excluded a total of 73 references for 35 studies with complete agreement between the authors. Details of studies which failed to meet the inclusion criteria were recorded in '<a href="./references#CD010509-sec-0124" title="">Characteristics of excluded studies</a>'. One study (<a href="./references#CD010509-bbs2-0048" title="NCT01636401 . Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01636401 (accessed 1 May 2014). ">NCT01636401</a>) had been completed but the results were not available and it was awaiting classification. Another ongoing study (<a href="./references#CD010509-bbs2-0049" title="NCT01966107 . Evaluate the effect of aclidinium bromide on long‐term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). http://clinicaltrials.gov/ct2/show/NCT01966107 (accessed 1 May 2014). ">ASCENT COPD</a>) is expected to be completed by January 2018. We identified a total of 12 studies reported in 59 references that were eligible for inclusion. For details of the search results please see <a href="#CD010509-fig-0001">Figure 1</a>. We asked Forest Research Institute if there were any additional study reports or references to studies that they had sponsored, but there was no reply. Two of the included studies (<a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>) were in abstract form and upon request we received the required information for <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a> from <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>. They also provided data for <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a> and <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>. From the correspondence, <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a> data was in the public domain at the American Thoracic Society (ATS) conference in San Diego in May 2014. </p> <div class="figure" id="CD010509-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010509-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010509-sec-0057"> <h4 class="title">Included studies</h4> <p>See <a href="#CD010509-tbl-0003">Table 1</a> for an overview of the included studies. </p> <div class="table" id="CD010509-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severity of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of aclidinium</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of aclidinium</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200, 400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200, 400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200, 400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(ATS)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25, 50, 100, 200,</p> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> </tbody> </table> </div> <section id="CD010509-sec-0058"> <h5 class="title">Study design and duration</h5> <p>All trials were randomised, double‐blind, parallel group, multicentre studies. One trial (<a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) was open label for the tiotropium arm but double blind for the aclidinium and placebo arms. Six trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II;</a><a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) studied aclidinium bromide and placebo. In the two trials of <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> and <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>, aclidinium bromide was assessed in comparison to both placebo and tiotropium bromide. Four trials (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>) studied aclidinium bromide versus placebo and formoterol along with a fixed dose combination of aclidinium and formoterol. <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a> was the 28‐week extension study of <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; the participants who agreed to participate in the extension study were kept on the same treatment and placebo arms as in the primary study. </p> <p>The trials were of different study duration, ranging from four to 52 weeks, with a mean of 20.7 weeks. Six of the included studies were of short duration with two trials each having a duration of four weeks (<a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>), six weeks (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) and 12 weeks (<a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>). The rest were long duration trials, with two studies of 52 weeks duration (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>), one study of 28 weeks duration (<a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>) and three studies of 24 weeks duration (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>). </p> </section> <section id="CD010509-sec-0059"> <h5 class="title">Setting</h5> <p>Most of the studies were based in the US and Canada (<a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>). Other study locations were in Europe (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>), Australia and New Zealand (<a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>), South Africa (<a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>) and Korea (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>). </p> </section> <section id="CD010509-sec-0060"> <h5 class="title">Participants</h5> <p>A total of 9547 participants were randomised in 12 eligible studies. The largest trial was <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a> with 1729 participants, whilst <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a> had the fewest participants with a total of 181. The remaining trials had numbers of participants ranging from 414 to 1692. The participants were current or former cigarette smokers with a smoking history of ≥ 10 pack years who were diagnosed with stable COPD according to the GOLD criteria and with a post‐bronchodilator FEV1/FVC ratio of &lt; 70% and FEV1 &lt; 80% of predicted value (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>). American Thoracic Society (ATS) criteria were used for diagnosis of COPD in patients with a smoking history of ≥ 10 pack years in one other trial (<a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>). No detailed information was available for COPD diagnosis for <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>. </p> <p>The trials were conducted in adults ≥ 40 years of age, including both male and female patients (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>). There was no specific description of age for the participants of <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>. The mean age of the participants ranged from 61.7 to 65.6 years and the majority were males. More than 90% of the participants were Causacians. </p> <p>Participants had moderate to severe COPD according to the GOLD criteria with FEV1 ≥ 30% and &lt; 80% in 10 studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>) and moderate to severe COPD according to the ATS criteria in one trial (<a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>). Moderate to severe COPD patients were also enrolled in <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>, however the specific criteria used for severity assessment were not mentioned. The participants' mean post‐bronchodilator FEV1 was between 46% and 57.6% predicted normal in the trials. Their baseline mean FEV1 was 1.21 L to 1.51 L and the mean St George's Respiratory Questionnaire score (SGRQ) score ranged from 45.1 to 50.4. </p> </section> <section id="CD010509-sec-0061"> <h5 class="title">Interventions</h5> <p>The participants underwent a two‐week run‐in period to ensure disease stability and washout of disallowed medications in eight trials with full text publications (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). </p> <p>An aclidinium dose of 200 μg was studied in the only or one of the intervention arms in eight trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>). A higher dose of 400 μg was studied in eight trials in one of the treatment arms (<a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>). Three studies (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>) and <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> studied aclidinium 400 μg and 200 μg, respectively, in comparison to formoterol and placebo together with fixed dose combination arms of aclidinium plus various doses of formoterol. <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a> was the extension study of <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a> in which the patients who completed <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a> and agreed to participate were kept on the same intervention in a double‐blind fashion for another 28 weeks. </p> <p>Aclidinium was given once daily in five trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>) while a twice daily dosage was used in the other seven trials (<a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>). </p> <p>Administration of aclidinium was by inhalation via a novel, multidose dry powder inhaler (Genuair) in 10 trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>), whereas either a Genuair or Pressair inhaler was used to deliver aclidinium in two studies (<a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>). </p> <p>Tiotropium was delivered by the Handihaler in <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> and <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; the latter was an open label study. Formoterol was studied as one of the interventions in <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a> and <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> where it was given via a Genuair inhaler, which was not an approved inhaler for formoterol. </p> </section> <section id="CD010509-sec-0062"> <h5 class="title">Concomitant medications</h5> <p>The participants were permitted to continue inhaled corticosteroids (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>), systemic corticosteroids (oral or parenteral) at doses equivalent to prednisone ≤ 10 mg/day or 20 mg every other day (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) and oral sustained‐release theophylline (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) provided the administration of these medications was stable for at least four weeks prior to screening; these medications had to be discontinued at least six hours before each study visit. Use of salbutamol or albuterol as rescue medication was also allowed (<a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). Oxygen therapy for less than 15 hours per day could be continued but not for two hours before study visits (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). In <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a> inhaled anticholinergics and LABAs were specifically mentioned as not allowed during the study period. </p> </section> <section id="CD010509-sec-0063"> <h5 class="title">Outcomes</h5> <p>The primary outcomes of the included studies were not identical with our review's primary outcomes because most of the individual trials assessed lung function as the primary outcome. Change from baseline in the morning pre‐dose (trough) FEV1 was the primary outcome in eight individual trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>), which was analysed as a secondary outcome in this review. Quality of life measured by the SGRQ, one of the primary outcomes of our review, was studied in the same eight trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) either as the change from baseline or as the percentage of participants who achieved the minimal clinically important difference (that is ≥ four unit decrease in SGRQ total score). Most of the data for the other primary outcomes of mortality and exacerbations were well reported in the trials and the authors also provided further necessary information regarding the number of patients with exacerbations who required a short course of oral steroids or antibiotics, or both. </p> <p>None of the included studies assessed functional capacity by the six‐minute walking distance, which was one of the secondary outcomes of our review. Specific data on hospital admissions due to exacerbations were also not mentioned in the published texts. However, the trial investigators provided the required data for this outcome. Other secondary outcomes of this review such as adverse events, non‐fatal serious adverse events and withdrawals were well reported. Data in the format required for the meta‐analysis of some of the secondary outcomes, especially lung function and TDI score, were kindly provided on request. </p> </section> <section id="CD010509-sec-0064"> <h5 class="title">Funding</h5> <p>Studies were sponsored by <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>, SA, Barcelona, Spain or Forest Laboratories, Inc, NY, USA. </p> </section> </section> <section id="CD010509-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 35 studies with 73 references as they failed to meet the eligibility criteria of our review (see <a href="./references#CD010509-sec-0124" title="">Characteristics of excluded studies</a> for details). Thirteen had a cross‐over study design; eight were phase one studies conducted in healthy participants; five lacked aclidinium as one of the treatment arms; four were reports of pooled data; three assessed the efficacy of and preferences for inhalers; and two studied aclidinium without a comparator. </p> </section> </section> <section id="CD010509-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>Generally the included studies had good methodological quality with low risk of bias in most of the domains. Detailed assessment of risk of bias across all studies is presented in <a href="./references#CD010509-sec-0123" title="">Characteristics of included studies;</a> and <a href="#CD010509-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD010509-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010509-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010509-sec-0067"> <h4 class="title">Allocation</h4> <p>One published study (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>) provided detailed information on random sequence generation by a computer generated schedule and allocation concealment via an interactive voice‐response system (IVRS). Although not explicitly described in the trial reports, from correspondence all <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial. This was used to assign a treatment sequence to a randomisation number by the statistics and programming group within <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>, according to the relevant standard operating procedures. The randomisation was performed in order to avoid any possible bias. The block size was determined in agreement with the clinical trial manager and the statistician and was not to be communicated to the investigators. In all studies, the IVRS (and in some cases an interactive web‐response system (IWRS)) was used to sequentially randomise patients to the intervention arms according to the randomisation ratio defined in each study as well as the block size that was determined by the sponsor (<a href="./appendices#CD010509-sec-0109">Appendix 3</a>). Since <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> was available as an abstract only, the information was insufficient to accurately assess the selection bias. </p> </section> <section id="CD010509-sec-0068"> <h4 class="title">Blinding</h4> <p>All of the included studies had a double‐blind design with blinding of participants, caregivers and investigators. From correspondence, blinding was applicable for all study outcomes. In the placebo‐controlled studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II;</a><a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013;</a><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010;</a><a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>) matching placebo was prepared to have the same external appearance with the same composition except for the active ingredient so that the aclidinium bromide and placebo were indistinguishable. In <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> the tiotropium arm was open label, though the trial was double‐blinded for the aclidinium and placebo arms, causing a high risk of bias for the comparison with tiotropium but a low risk of bias for the comparison with placebo. For all trials, outcome assessors remained blinded with regard to the treatment assignments throughout the study period. Independent blinded experts and reviewers were assigned for analysing the spirometry data and dyspnoea scores (baseline dyspnoea index (BDI) and TDI). A double‐dummy technique was applied in <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> to ensure the double‐blinding of the trial in order to minimise bias. </p> </section> <section id="CD010509-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>All eight full text trials (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) reported the number of dropouts, along with the reasons, for all the study arms. The number of and reasons for withdrawals for three trials (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>) were kindly provided on request by the investigators. However, <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> did not report sufficient information to assess attrition bias. Nine of the included studies were rated as having a low risk of bias, either because the number of dropouts was considered low and was balanced between groups (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>), because withdrawal rates were high but evenly distributed across study arms (<a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>), or because withdrawal rates were regarded as acceptable given the methods of imputation reported in the published articles (<a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>). Efficacy analyses and safety outcomes were performed on the intention‐to‐treat population which consisted of all randomised patients who received at least one dose of study medication and who had a baseline and at least one post‐baseline FEV1 assessment (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). The last observation carried forward approach was used to impute missing data (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>). The remaining three trials were rated as unclear because of uneven dropouts and with no clear information on the methods of imputation (<a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) or because of unavailable data for dropouts (<a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>). </p> </section> <section id="CD010509-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Seven published trials reported all the outcomes documented in the methodology section of the published manuscripts without any apparent bias (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). The pre‐specified outcomes of the three trials (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>) were supplied on request, with no detectable reporting bias. There were two unreported outcomes, namely trough FVC and peak expiratory flow rate (PEFR), in the <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> trial though these outcome measures were specified in the methodology. Limited information prevented full assessment of reporting bias for <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>. </p> </section> <section id="CD010509-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>The studies were sponsored and funded by manufacturers of aclidinium, <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>, SA, Barcelona, Spain and Forest Laboratories, Inc, NY, USA, and some of the authors received financial support from the same, all of which were declared with no potential source of bias. <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> was published as an abstract in 2010 but as of 2014 has failed to be published as full text, thus publication bias could not be ruled out. In <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> the baseline mean FEV1 was 1.40 L for the aclidinium 200 μg arm, 1.25 L for the aclidinium 400 μg arm and 1.46 L for the placebo arm. This relative imbalance in baseline lung function was taken into consideration in performing the meta‐analysis and judged as not causing a significant high risk of bias. </p> </section> </section> <section id="CD010509-sec-0072"> <h3 class="title" id="CD010509-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD010509-tbl-0001"><b>Summary of findings for the main comparison</b> Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease</a>; <a href="./full#CD010509-tbl-0002"><b>Summary of findings 2</b> Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease</a> </p> <p>We included data from 10 studies for quantitative synthesis (meta‐analysis) in the comparison of aclidinium bromide versus placebo (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). Two studies (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) assessed tiotropium as well and these data were pooled for the comparison of aclidinium bromide versus LAMA. Four trials (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>) included both aclidinium and formoterol as intervention arms, however formoterol was given via the Genuair inhaler in these studies thus the data were considered inappropriate for comparison of aclidinium bromide versus LABA. </p> <section id="CD010509-sec-0073"> <h4 class="title">1. Aclidinum bromide versus placebo</h4> <section id="CD010509-sec-0074"> <h5 class="title">Primary outcomes</h5> <section id="CD010509-sec-0075"> <h6 class="title">Mortality (all‐cause)</h6> <p>The number of deaths was reported in nine studies involving a total of 5252 participants (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). Overall, there was no statistically significant difference in the number of deaths between the aclidinium and placebo groups (OR 0.92; 95% CI 0.43 to 1.94, low quality evidence; <a href="./full#CD010509-tbl-0001">summary of findings Table for the main comparison</a>). Five patients out of 1000 (95% CI 2 to 10) patients receiving aclidinium died over 6 to 52 weeks, which was similar to the placebo group. Subgroup analysis of aclidinium once daily and twice daily showed an OR of 0.63 (95% CI 0.25 to 1.60; 3 trials, 1828 participants) and an OR of 1.69 (95% CI 0.46 to 6.21; 6 trials, 3424 participants) respectively (<a href="./references#CD010509-fig-0007" title="">Analysis 1.1</a>). There was no significant difference between the subgroups. </p> </section> <section id="CD010509-sec-0076"> <h6 class="title">Exacerbations requiring a short course of an oral steroid or antibiotic, or both</h6> <p>Overall, data from 10 trials involving 5624 participants were pooled for patients experiencing at least one COPD exacerbation requiring a short course of oral steroids or antibiotics, or both (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). The exact data for the trials which did not specifically mention the number of moderate exacerbations requiring oral steroids, antibiotics or both were kindly supplied by the sponsors. Aclidinium demonstrated a non‐significant reduction in moderate exacerbations compared to placebo (OR 0.88; 95% CI 0.74 to 1.04, moderate quality evidence). In patients on aclidinium, 122 people out of 1000 (95% CI 105 to 141) had exacerbations over 4 to 52 weeks, compared to 137 out of 1000 for patients on placebo (<a href="./full#CD010509-tbl-0001">summary of findings Table for the main comparison</a>). In the subgroup analysis there was no significant difference between once daily (OR 0.93; 95% CI 0.73 to 1.20; 4 trials, 2201 participants) and twice daily aclidinium (OR 0.83; 95% CI 0.66 to 1.05; 6 trials, 3423 participants; test for subgroup differences: P = 0.51, <a href="./references#CD010509-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD010509-sec-0077"> <h6 class="title">Quality of life</h6> <p>Quality of life was assessed by the SGRQ in seven studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>), either as the change from the baseline mean value or as the percentage of patients who achieved the minimal clinically important difference in SGRQ total score of ≥ four units reduction. Some of the data, in the format necessary for pooling, were kindly provided by the sponsors. Meta‐analysis of both measurements showed a statistically significant improvement with aclidinium bromide in comparison to placebo. Overall, aclidinium decreased the SGRQ total score by a mean difference of ‐2.34 units compared with placebo (95% CI ‐3.18 to ‐1.51; 7 trials, 4442 participants). A significant reduction in SGRQ total score was observed for both aclidinium once daily (MD ‐1.96; 95% CI ‐3.47 to ‐0.45; 2 trials, 1560 participants) and twice daily (MD ‐2.51; 95% CI ‐3.50 to ‐1.51; 5 trials, 2882 participants) with no significant difference between subgroups (test for subgroup differences: P = 0.55, <a href="./references#CD010509-fig-0009" title="">Analysis 1.3</a>). </p> <p>More patients on aclidinium reported a clinically significant improvement (a fall of at least four units in SGRQ total score) in quality of life than in the placebo group, which was of statistical significance (OR 1.49; 95% CI 1.31 to 1.70; 7 trials, 4420 participants; <a href="./references#CD010509-fig-0010" title="">Analysis 1.4</a>). A total of 494 per 1000 patients on aclidinium (95% CI 462 to 527) compared to 396 out of 1000 patients on placebo achieved a clinically important improvement in SGRQ score, the quality of evidence being rated as high (<a href="./full#CD010509-tbl-0001">summary of findings Table for the main comparison</a>). In absolute terms, 98 more per 1000 (from 66 more to 131 more) patients on aclidinium experienced clinically meaningful improvements in quality of life than on placebo over 12 to 52 weeks. For every 10 people treated with aclidinium instead of placebo, one additional person was estimated to achieve this clinically important improvement in quality of life (NNT = 10; 95% CI 8 to 15). Both twice daily (OR 1.55; 95% CI 1.32 to 1.81; 5 trials, 2860 participants) and once daily aclidinium (OR 1.36; 95% CI 1.08 to 1.73; 2 trials, 1560 participants) demonstrated significant improvement with no statistical difference in the subgroup analysis (test for subgroup differences: P = 0.38; <a href="#CD010509-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010509-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score." data-id="CD010509-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score. </p> </div> </div> </div> </section> </section> <section id="CD010509-sec-0078"> <h5 class="title">Secondary outcomes</h5> <section id="CD010509-sec-0079"> <h6 class="title">Lung function</h6> <p>Nine trials studied changes from baseline in trough and peak FEV1, and trough and peak FVC (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) and seven studies reported the change from baseline in normalised FEV1 area under the curve in the first 12 hours (FEV1 AUC<sub>0‐12</sub>) (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>). Most of the trials reported the data for these outcomes as the difference in aclidinium versus placebo values, but the required data for each intervention arm and placebo arm for our meta‐analysis were kindly provided by <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>. These were pooled as the change from baseline to the end of the study. </p> <p>The predose FEV1 for participants taking aclidinium was increased by 0.09 L (or 90 mL) at the end of the trials compared with participants using placebo inhalers (95% CI 0.08 to 0.10; 9 trials, 4963 participants). A greater improvement in the trough FEV1 was noted with twice daily dosing (MD 0.10; 95% CI 0.09 to 0.12; 6 trials, 3164 participants) compared to once daily (MD 0.07; 95% CI 0.05 to 0.09; 3 trials, 1799 participants; test for subgroup differences: P = 0.02, <a href="./references#CD010509-fig-0011" title="">Analysis 1.5</a>). </p> <p>The meta‐analysis for peak FEV1 change from baseline, using the random‐effects model due to significant heterogeneity (I<sup>2</sup> = 56%), yielded an overall MD of 0.17 L (95% CI 0.15 to 0.20; 9 trials, 4962 participants). No difference in the pooled MD was observed between twice daily (MD 0.17; 95% CI 0.15 to 0.19; 6 trials, 3160 participants) and once daily aclidinium (MD 0.19; 95% CI 0.12 to 0.25; 3 trials, 1802 participants; test for subgroup differences: P = 0.62, <a href="./references#CD010509-fig-0012" title="">Analysis 1.6</a>). </p> <p>Aclidinium resulted in a statistically significant improvement of normalised FEV1 AUC<sub>0‐12</sub> from baseline with a pooled MD of 0.13 L, or 130 mL, compared to placebo (95% CI 0.10 to 0.16; 7 trials, 1237 participants). The pooled MD for twice daily (MD 0.13; 95% CI 0.10 to 0.17; 5 trials, 1106 participants) and once daily aclidinium (MD 0.13; 95% CI 0.08 to 0.19; 2 trials, 131 participants) were similar (<a href="./references#CD010509-fig-0013" title="">Analysis 1.7</a>). </p> <p>The mean change in baseline trough FVC was 0.16 L greater with aclidinium than with placebo (95% CI 0.14 to 0.18; 9 trials, 4963 participants). There was no difference between twice daily (MD 0.17; 95% CI 0.14 to 0.20; 6 trials, 3164 participants) and once daily aclidinium (MD 0.14; 95% CI 0.10 to 0.18; 3 trials, 1799 participants; test for subgroup differences: P = 0.26, <a href="./references#CD010509-fig-0014" title="">Analysis 1.8</a>). </p> <p>The improvement in peak FVC from baseline was also significantly greater in patients on aclidinium compared to placebo with a pooled MD of 0.27 L (95% CI 0.23 to 0.31; 9 trials, 4962 participants) in the meta‐analysis using a random‐effects model as the heterogeneity was high (I<sup>2</sup> = 56%). Subgroup analysis demonstrated no significant difference between twice daily (MD 0.25; 95% CI 0.22 to 0.28; 6 trials, 3160 participants) and once daily aclidinium (MD 0.33; 95% CI 0.23 to 0.42; 3 trials, 1802 participants; test for subgroup differences: P = 0.13, <a href="./references#CD010509-fig-0015" title="">Analysis 1.9</a>). </p> </section> <section id="CD010509-sec-0080"> <h6 class="title">Functional capacity</h6> <p>None of the individual studies measured functional capacity.</p> </section> <section id="CD010509-sec-0081"> <h6 class="title">Hospital admissions due to exacerbations</h6> <p>The published reports of the included studies did not specifically mention hospital admissions due to either exacerbations or any cause. However, data for hospital admissions due to exacerbations, that is severe COPD exacerbations, were obtained for 10 studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) from the study sponsors. </p> <p>There were fewer patients on aclidinium who suffered one or more exacerbation(s) leading to hospitalisation than on placebo over 4 to 52 weeks (OR 0.64; 95% CI 0.46 to 0.88; 10 studies, 5624 participants) (<a href="#CD010509-fig-0004">Figure 4</a>). Twenty four patients per 1000 (95% CI 17 to 33) on aclidinium suffered from at least one severe COPD exacerbation requiring hospital admission compared to 37 per 1000 on placebo, the quality of evidence being classified as high (<a href="./full#CD010509-tbl-0001">summary of findings Table for the main comparison</a>). In absolute terms, aclidinium resulted in 13 fewer patients with exacerbation‐related hospitalisations per 1000 (4 to 20 fewer) than placebo. It was estimated that for every 77 patients treated with aclidinium instead of placebo, one additional person was free from a severe COPD exacerbation necessitating hospitalisation (NNT = 77; 95% CI 51 to 233). Subgroup analysis showed that the difference between twice daily (OR 0.59; 95% CI 0.35 to 1.01; 6 trials, 3423 participants) and once daily aclidinium (OR 0.67; 95% CI 0.45 to 0.99; 4 trials, 2201 participants) was not statistically significant (test for subgroup differences: P = 0.73, <a href="./references#CD010509-fig-0016" title="">Analysis 1.10</a>). </p> <div class="figure" id="CD010509-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.10 Number of patients with hospital admissions due to COPD exacerbation." data-id="CD010509-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.10 Number of patients with hospital admissions due to COPD exacerbation. </p> </div> </div> </div> </section> <section id="CD010509-sec-0082"> <h6 class="title">Improvement in symptoms</h6> <p>Changes in symptom of dyspnoea were assessed in eight studies using the transitional dyspnoea index (TDI) score (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) and reported as either the change in mean value from baseline or as percentage of participants who achieved the minimal clinically important difference in TDI focal score of ≥ one unit increment. </p> <p>Patients on aclidinium reported a MD of 0.84 units improvement in TDI compared with placebo (95% CI 0.50 to 1.18; 8 trials, 4490 participants) using a random‐effects model as the heterogeneity was high (I<sup>2</sup> = 68%). This heterogeneity was caused by <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> in which the patients on aclidinium had a relatively lower baseline FEV1 with more severe disease (GOLD stage III) than in the placebo arm. Repeating the analysis with the exclusion of this particular study resulted in a MD of 0.95 units (95% CI 0.72 to 1.19) without heterogeneity (I<sup>2</sup> = 0%). Both once daily (MD 1.08; 95% CI 0.46 to 1.71; 3 trials, 1597 participants) and twice daily aclidinium (MD 0.72; 95% CI 0.33 to 1.11; 5 trials, 2893 participants) demonstrated an improvement in TDI focal score with no statistical difference in the subgroup analysis (test for subgroup differences: P = 0.33, <a href="./references#CD010509-fig-0017" title="">Analysis 1.11</a>). </p> <p>In terms of percentage of COPD patients achieving ≥ one unit improvement in TDI focal score for dyspnoea, more patients on aclidinium attained this minimal clinically important difference than for those on placebo (OR 1.73; 95% CI 1.52 to 1.98; 8 trials, 4289 participants; I<sup>2</sup> = 0%). A similar improvement was noted for both once daily (OR 1.75; 95% CI 1.39 to 2.20; 3 trials, 1589 participants) and twice daily aclidinium (OR 1.72; 95% CI 1.47 to 2.03; 5 trials, 2700 participants; test for subgroup differences: P = 0.92, <a href="./references#CD010509-fig-0018" title="">Analysis 1.12</a>). </p> </section> <section id="CD010509-sec-0083"> <h6 class="title">Non‐fatal serious adverse events</h6> <p>Ten studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>) reported this outcome with participants as the level of analysis (that is the number of people who had non‐fatal serious adverse events as opposed to the number of adverse events in total). When the findings of these studies were pooled, no difference was observed between aclidinium and placebo (OR 0.89; 95% CI 0.70 to 1.14; 10 trials, 5651 participants) (<a href="#CD010509-fig-0005">Figure 5</a>). Among 1000 patients, 50 receiving aclidinium (95% CI 40 to 64) and 56 on placebo developed non‐fatal serious adverse events, with moderate quality of evidence (<a href="./full#CD010509-tbl-0001">summary of findings Table for the main comparison</a>). This result appeared to be independent of dosing (twice daily OR 0.95; 95% CI 0.68 to 1.34; 6 trials, 3424 participants; once daily OR 0.83; 95% CI 0.58 to 1.18; 4 trials, 2227 participants; test for subgroup differences: P = 0.57, <a href="./references#CD010509-fig-0019" title="">Analysis 1.13</a>). </p> <div class="figure" id="CD010509-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.13 Non‐fatal serious adverse events." data-id="CD010509-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.13 Non‐fatal serious adverse events. </p> </div> </div> </div> </section> <section id="CD010509-sec-0084"> <h6 class="title">Withdrawals</h6> <p>Withdrawals due to either lack of efficacy or adverse events were provided in 10 studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>). </p> <p>There was a statistically and clinically significant reduction in withdrawals due to lack of efficacy with aclidinium compared to placebo (OR 0.31; 95% CI 0.23 to 0.43; 10 trials, 5672 participants). The effect estimates were similar for twice daily (OR 0.32; 95% CI 0.20 to 0.51; 6 trials, 3445 participants) and once daily aclidinium (OR 0.31; 95% CI 0.20 to 0.47; 4 trials, 2227 participants; test for subgroup differences: P = 0.91, <a href="./references#CD010509-fig-0020" title="">Analysis 1.14</a>). </p> <p>Overall, aclidinium resulted in a non‐significant reduction in withdrawals due to adverse events compared with placebo (OR 0.76; 95% CI 0.57 to 1.01; 10 trials, 5672 participants). No significant difference was observed for once daily dosing (OR 0.65; 95% CI 0.42 to 1.00; 4 trials, 2227 participants) and twice daily dosage regimens (OR 0.84; 95% CI 0.59 to 1.21; 6 trials, 3445 participants; test for subgroup differences: P = 0.36, <a href="./references#CD010509-fig-0021" title="">Analysis 1.15</a>). </p> </section> </section> </section> <section id="CD010509-sec-0085"> <h4 class="title">2. Aclidinum bromide versus long‐acting muscarinic antagonist</h4> <section id="CD010509-sec-0086"> <h5 class="title">Primary outcomes</h5> <p>There were no deaths reported for both the aclidinium and tiotropium arms in a total of 329 patients in <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> (<a href="./references#CD010509-fig-0022" title="">Analysis 2.1</a>). </p> <p>Two studies assessed exacerbations requiring a short course of oral steroids or antibiotics, or both, in 729 participants (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> ; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>). Aclidinium was associated with a higher number of exacerbations compared to tiotropium but this was not statistically significant (OR 2.64; 95% CI 0.31 to 22.18) (<a href="./references#CD010509-fig-0023" title="">Analysis 2.2</a>). There were no patients with moderate exacerbations in the tiotropium arm compared to five of 506 participants in the aclidinium arm. However, the quality of evidence was very low because of the high risk of bias in <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>, which was open label for the tiotropium arm and had very serious imprecision of the results (<a href="./full#CD010509-tbl-0002">summary of findings Table 2</a>). </p> <p>None of the studies measured quality of life for aclidinium and tiotropium.</p> </section> <section id="CD010509-sec-0087"> <h5 class="title">Secondary outcomes</h5> <p>Only one trial provided data for aclidinium and tiotropium on lung function (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>). Aclidinium was associated with a greater improvement in trough FEV1 (MD 0.04; 95% CI ‐0.01 to 0.09; 1 trial, 329 participants) (<a href="./references#CD010509-fig-0024" title="">Analysis 2.3</a>), peak FEV1 (MD 0.01; 95% CI ‐0.04 to 0.06; 1 trial, 329 participants) (<a href="./references#CD010509-fig-0025" title="">Analysis 2.4</a>), trough FVC (MD 0.08; 95% CI ‐0.01 to 0.17; 1 trial, 329 participants) (<a href="./references#CD010509-fig-0026" title="">Analysis 2.5</a>) and peak FVC (MD 0.04; 95% CI ‐0.05 to 0.13; 1 trial, 329 participants) (<a href="./references#CD010509-fig-0027" title="">Analysis 2.6</a>) than tiotropium, however none were statistically significant. </p> <p>Functional capacity was not assessed in the two studies included in this comparison.</p> <p>Aclidinium reduced the number of patients with hospitalisations due to COPD exacerbations compared to tiotropium but the difference was not statistically significant (OR 0.54; 95% CI 0.07 to 4.11; 2 trials, 729 participants) (<a href="./references#CD010509-fig-0028" title="">Analysis 2.7</a>). Two patients per 1000 (95% CI 0 to 18) on aclidinium versus four patients per 1000 on tiotropium were admitted to hospital for severe COPD exacerbations, but this was very low level evidence (<a href="./full#CD010509-tbl-0002">summary of findings Table 2</a>). The wide CI included the possibility of no difference. </p> <p>Data from the two trials (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> ; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) were combined for non‐fatal serious adverse events. Aclidinium demonstrated a non‐significant reduction in non‐fatal serious adverse events compared with tiotropium (OR 0.67; 95% CI 0.17 to 2.65; 2 trials, 729 participants) (<a href="./references#CD010509-fig-0029" title="">Analysis 2.8</a>). In a total of 1000 patients, 12 on aclidinium (95% CI 3 to 46) and 18 on tiotropium experienced non‐fatal serious adverse events over a period of four to six weeks, with a very low quality of evidence as the CIs were wide. </p> <p>Both <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> and <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> reported withdrawals due to lack of efficacy or adverse events. There were no withdrawals due to lack of efficacy for both aclidinium and tiotropium in these two studies (<a href="./references#CD010509-fig-0030" title="">Analysis 2.9</a>). No significant difference existed between aclidinium and tiotropium for withdrawals due to adverse events (OR 0.94; 95% CI 0.26 to 3.42; 2 trials, 729 participants) (<a href="./references#CD010509-fig-0031" title="">Analysis 2.10</a>). </p> </section> </section> <section id="CD010509-sec-0088"> <h4 class="title">3. Aclidinum bromide versus long‐acting beta<sub>2</sub>‐agonist </h4> <p>Inadequate and inaccurate data limited this comparison as formoterol was given via the Genuair inhaler in the trials, which was not an approved inhaler for formoterol (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>). </p> </section> <section id="CD010509-sec-0089"> <h4 class="title">4. Adverse events</h4> <p>Adverse events with aclidinium were reported in a total of 10 studies (<a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a>; <a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a>; <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>; <a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a>). We have presented the adverse event data from both comparisons with placebo and tiotropium in section 4 of <a href="./references#CD010509-sec-0100" title="">Data and analyses</a>. </p> <p>A lower incidence of cardiac events (<a href="./references#CD010509-fig-0032" title="">Analysis 4.1</a>) was more prominent with aclidinium compared to tiotropium and placebo, but both were statistically non‐significant. There was no significant difference between aclidinium and placebo or tiotropium for the anticholinergic side effect of dry mouth (<a href="./references#CD010509-fig-0033" title="">Analysis 4.2</a>). Constipation was non‐significantly more frequent with aclidinium compared to both placebo and tiotropium (<a href="./references#CD010509-fig-0034" title="">Analysis 4.3</a>). Aclidinium non‐significantly decreased cerebrovascular events (<a href="./references#CD010509-fig-0035" title="">Analysis 4.4</a>) compared to placebo (OR 0.58; 95% CI 0.25 to 1.33; 9 trials, 5252 participants). However, in <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> cerebrovascular events were more frequent with aclidinium compared to tiotropium but the CIs were very wide and the difference was not statistically significant (OR 2.79; 95% CI 0.11 to 68.96; 1 trial, 329 participants). </p> <p>Diarrhoea was found to be significantly increased with aclidinium (once daily therapy) compared to placebo (OR 2.32; 95% CI 1.14 to 4.74; 2 trials, 1647 participants). However, no statistical difference was observed between once daily and twice daily aclidinium (OR 1.06; 95% CI 0.63 to 1.78; 5 trials, 3168 participants; test for subgroup differences: P = 0.08, <a href="./references#CD010509-fig-0036" title="">Analysis 4.5</a>). </p> <p>Other reported adverse events such as nasopharyngitis, headache, cough, hypertension, respiratory tract infections, urinary tract infections, fatigue, dizziness, dyspnoea, arthralgia, back pain and oropharyngeal pain showed no significant difference between aclidinium and placebo or tiotropium in the pooled analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010509-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010509-sec-0090"></div> <section id="CD010509-sec-0091"> <h3 class="title" id="CD010509-sec-0091">Summary of main results</h3> <p>We calculated summary estimates of the effects of aclidinium on clinical outcomes in comparison to placebo and tiotropium. Aclidinium improved quality of life and reduced exacerbation‐related hospitalisations compared to placebo. Aclidinium significantly lowered the SGRQ total score by 2.34 units (from 3.18 to 1.51 lower), although this mean improvement did not reach the accepted threshold of four units for a clinically important difference. However, more patients on aclidinium achieved a minimal clinically important difference of at least four units decrease in the SGRQ total score (462 to 527 per 1000) than those on placebo (396 per 1000). A total of 10 patients need to be treated with aclidinium to attain one additional person with a four unit improvement in SGRQ total score. Similarly, aclidinium significantly reduced the number of patients with exacerbation‐related hospital admissions compared to placebo (17 to 33 per 1000 versus 37 per 1000), which would correspond to approximately 77 patients having to be treated with aclidinium to prevent one additional exacerbation‐related hospitalisation. However, aclidinium therapy failed to demonstrate a significant reduction in the number of patients experiencing an exacerbation that required an oral steroid or antibiotic, or both. In terms of safety, no significant difference between aclidinium and placebo was observed in all‐cause mortality or non‐fatal serious adverse events. All reported deaths in the trials were not related to aclidinium therapy. </p> <p>For the secondary outcomes, improvements in symptom scales and spirometric indices appeared clinically significant with aclidinium compared to placebo. Patients treated with aclidinium experienced clinically significant improvements in dyspnoea with a TDI focal score change from baseline of 0.50 to 1.18 units. Exclusion of the data from <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> with its baseline imbalance in COPD severity resulted in a larger increase in the TDI focal score of 0.72 to 1.19 units, without significant heterogeneity. The proportion of patients on aclidinium who exceeded the minimum clinically important difference of one unit in TDI focal score was higher than with placebo. Lung function measurements of trough and peak FEV1, trough and peak FVC and normalised FEV1 area under the curve in the first 12 hours (FEV1 AUC<sub>0‐12</sub>) were significantly higher with aclidinium compared to placebo. A significantly lower number of participants withdrew from studies due to lack of efficacy in the aclidinium group compared to the placebo group. Similarly, fewer withdrawals due to adverse events were observed among patients on aclidinium than on placebo, but the differences were not statistically significant. We could not show a difference in most of the efficacy outcomes related to dosing of aclidinium, except for trough FEV1 where the twice daily dosage demonstrated a relatively superior improvement compared with the once daily regimen. </p> <p>Evaluation of the effects of aclidinium in relation to LABAs was unsuccessful due to a lack of trials of good design and inaccurate data. </p> <p>For the comparison of aclidinium and LAMAs, we were able to pool the data from two studies (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) which included tiotropium as one of the intervention arms. Based on the currently available, limited data, aclidinium did not differ significantly from tiotropium in terms of exacerbations requiring oral steroids or antibiotics, or both, exacerbation‐related hospitalisations and non‐fatal serious adverse events. There were no reported cases of deaths or withdrawals due to lack of efficacy for both aclidinium and tiotropium. Withdrawals due to adverse events were similar with aclidinium in comparison to tiotropium. Patients treated with aclidinium had greater improvements in the spirometric indices of trough FEV1, peak FEV1, trough FVC and peak FVC than with tiotropium. However, only <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> contributed to the lung function outcomes and the evidence for the other outcomes were of very low quality, thus reducing our confidence in the conclusions. Therefore, we strongly recommend future trials comparing the effects of aclidinium and tiotropium to strengthen our confidence in conclusions about the efficacy of this novel LAMA in relation to established LAMAs. </p> <p>There was no statistically significant difference between the number of participants suffering from non‐serious adverse events with aclidinium compared to placebo and tiotropium. Concern about a possible cardiovascular risk with aclidinium was not reinforced in our review as the risk did not differ from placebo or tiotropium. This was also in accordance with the greater kinetic selectivity of aclidinium on M3 over M2 receptors (<a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>; <a href="./references#CD010509-bbs2-0082" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. [PUBMED: 22003291] ">Sims 2011</a>). Interestingly, patients on once daily aclidinium developed diarrhoea more often than with placebo but this was not of clinical importance. However, further trials are needed in order to allow valid conclusions with regard to this. The numbers of anticholinergic side effects such as dry mouth and constipation were slightly higher with aclidinium than placebo but they were not of clinical or statistical significance. Other adverse events were comparable between aclidinium and placebo or tiotropium. </p> </section> <section id="CD010509-sec-0092"> <h3 class="title" id="CD010509-sec-0092">Overall completeness and applicability of evidence</h3> <p>There were substantial numbers of trials investigating aclidinium and placebo for this review, but the number of trials assessing aclidinium compared to tiotropium or formoterol were inadequate. Four of the included trials did investigate formoterol as one of the treatment arms (<a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a>; <a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>; <a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>; <a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a>) yet, from discussion with the study sponsors, both aclidinium and formoterol were delivered in Genuair inhalers to maintain double‐blindness. While aclidinium delivered in the Genuair is an approved drug, this is not the case for formoterol. Thus the data for formoterol were considered unsuitable to be included in our analysis. However, in two trials with tiotropium (<a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>; <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>) the tiotropium was administered in its approved HandiHaler. In <a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a>, two Genuair inhalers loaded with either aclidinium or placebo and one HandiHaler loaded with either tiotropium or placebo were supplied. To maintain blinding, patients were instructed to use both inhalers each morning and the Genuair only each evening. However, tiotropium delivered via the HandiHaler was open label for <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>. This study limitation decreased the quality of evidence for the treatment effects of this comparison. In this review, subgroup analysis was performed for dosing of aclidinium, once daily versus twice daily. Most of the once daily trials studied aclidinium 200 μg whereas twice daily trials studied mainly aclidinium 400 μg; some of the twice daily trials investigated both aclidinium 200 μg and 400 μg. These differences in the total daily dose among the trials might have impacted on the summary estimates of subgroups but with minimal alterations in the overall effect estimates. The results from this review indicate an improvement in the mean health‐related quality of life and a reduction in exacerbations requiring hospital admission for stable COPD patients on aclidinium compared to placebo. The mean improvement for these outcomes was statistically significant but was relatively small in relation to the minimum clinically important difference. However, there was a significant number of patients who had a clinically relevant improvement. The evidence that this review provides strengthens and supports the efficacy of aclidinium compared to placebo for use in patients with stable COPD. However, the lack of trials prevents a comprehensive assessment of the evidence on the efficacy of aclidinium compared to tiotropium or formoterol, or other LABAs or LAMAs. No significant increase in deaths, non‐fatal serious adverse events and other adverse events compared with placebo make aclidinium a relatively safe medication for use as maintenance therapy by patients with moderate to severe stable COPD. </p> </section> <section id="CD010509-sec-0093"> <h3 class="title" id="CD010509-sec-0093">Quality of the evidence</h3> <p>The studies included in this review were generally of good to excellent methodological quality and the single conference abstract, which was of unknown quality, did not contribute any data to the analysis. The inclusion and exclusion criteria for the trials were almost identical. The results were unlikely to be compromised by performance (selection and allocation) or detection biases as all trials were industry‐sponsored, in accordance with the pre‐specified protocol, and double‐blind; except for <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> where the tiotropium arm was open label. Selective reporting was considered to be at low risk with the exception of <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a>, where some of the lung function outcomes were not reported but none were outcomes of our review. The percentage of withdrawals in the included trials ranged from 6.3% to 42.2% for long‐term studies of more than12 weeks, whereas short‐term studies of 12 weeks or less had relatively lower withdrawal rates of 2.5% to 19.9%. However, most of the participants who completed treatment remained for follow‐up, the percentage of participants lost to follow‐up in the included trials being 0% to 3.4%. Missing data were imputed using the last observation carried forward approach in the individual studies. Several studies did not report on exacerbations requiring hospital admission or a short course of oral steroids or antibiotics, or both, and lung function data in a way that could be included in the review, however all these data were supplied by <a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>. All studies utilised intention‐to‐treat analysis. Visual inspection of the funnel plot for exacerbations with aclidinium and placebo did not suggest publication bias (<a href="#CD010509-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD010509-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.2 Number of patients with exacerbations requiring steroids, antibiotics or both." data-id="CD010509-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.2 Number of patients with exacerbations requiring steroids, antibiotics or both. </p> </div> </div> </div> <p>In particular, the quality of the evidence ranged from very low to high for the outcomes of this review. High quality evidence reinforced the validity of findings on quality of life and hospitalisations due to exacerbations, for aclidinium in comparison to placebo, while the evidence for mortality was low quality; the evidence on exacerbations requiring a short course of oral steroids or antibiotics, or both, and non‐fatal serious adverse events was rated as moderate. However, the evidence for the majority of outcomes for aclidinium versus tiotropium was of very low quality. We believe that additional information from future studies might change our confidence in these results and we will continue to update this review in an attempt to maximise the evidence to inform future clinical practice. </p> </section> <section id="CD010509-sec-0094"> <h3 class="title" id="CD010509-sec-0094">Potential biases in the review process</h3> <p>We made every effort to obtain grey literature in order to minimise the impact of publication bias. In addition to the Cochrane Airways Group's systematic electronic search, we performed a comprehensive search of other sources (for example searching drug company databases, clinical trial registration sites, and checking reference lists) for the identification of potentially relevant published and unpublished studies, with no language restrictions. The manufacturer was very helpful in providing additional information on completed published trials as well as completed but unpublished trials. Publication bias, therefore, was less likely, as supported by the funnel plot for the exacerbation data. Two review authors independently conducted trial selection and data extraction. We contacted authors for missing and incomplete data. To maximise the accuracy of our review, we requested the exact values of the data required in our meta‐analysis directly from the drug companies. We did not use data from estimations based on figures or other available indirect data. The manufacturer (<a href="./references#CD010509-bbs2-0052" title="Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014). ">Almirall</a>) was accommodating in supplying information about study designs, details of trials and missing data for several of the studies. Possible limitations of the meta‐analysis include double‐counting of patients from overlapping publications and trials. We avoided this potential concern of double counting by including only the results of the first period (24 weeks) of the primary study (<a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a>) instead of the data at the end (one year) of the extension study (<a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a>) as the extension period was not a truly randomised comparison and had substantial withdrawals. Clinical characteristics of the patients recruited into the trials and the disease severity as measured by baseline spirometry were similar between trials except for one trial (<a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>) in which there was a higher proportion of patients with lower baseline mean FEV1 in the aclidinium 400 µg arm (1.25 L) than in the placebo arm (1.46 L). Thus, we repeated our analysis of all outcome measures with the exclusion of this study to detect any alterations in the summary estimates of the effects of aclidinium. However, the clinical homogeneity of the majority of the trials yielded statistical homogeneity for many outcome measures across the trials, except for symptom improvement measured by change from baseline in mean TDI focal score where the effect estimate was significantly altered by the data from this study. Another potential source of bias could be concomitant medications, however medications had to be used at a stable dose for at least four weeks and were stopped at least six hours before each study visit in the primary trials, making any possible interaction with aclidinium less likely. </p> </section> <section id="CD010509-sec-0095"> <h3 class="title" id="CD010509-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>There are a number of published reviews on aclidinium in the current literature.</p> <p><a href="./references#CD010509-bbs2-0068" title="JonesP . Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Advances in Therapy2013;30(4):354‐68. [PUBMED: 23553509] ">Jones 2013</a> reported the efficacy of twice daily aclidinium and included the three studies <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> and <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>. Pooled data from <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a> and <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a> showed a statistically significant improvement in lung function (trough FEV1 and peak FEV1) and quality of life, which is in agreement with the results of our review. It, however, mentioned that aclidinium significantly reduced the frequency of exacerbations, which our review failed to prove. Pooled data from the two studies (<a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>) in that review showed a significant reduction in the rate of moderate to severe exacerbations for the aclidinium 400 μg dose when compared with placebo (0.31 versus 0.44; rate ratio 0.71; P = 0.01). Our review separately analysed moderate exacerbations that required a short course of oral steroids or antibiotics, or both, and severe exacerbations requiring hospital admissions. We also included trials of other doses of aclidinium, with a total of 10 studies in our meta‐analysis. We found that aclidinium reduced severe exacerbations necessitating hospitalisation but not moderate exacerbations requiring oral steroids or antibiotics, or both. </p> <p>A significant improvement in lung function with aclidinium over placebo in moderate to severe COPD was also reported in a meeting abstract by <a href="./references#CD010509-bbs2-0014" title="D'UrzoA , JonesP , FergusonG , RekedaL , GilEG , CaractaC . Aclidinium bromide improves lung function in a wide range of patients with moderate to severe COPD: Pooled subgroup analysis of the ACCORD COPD I and II and ATTAIN trials. Chest2013;144(4_Meeting abstracts):746A. ">D'Urzo 2013a</a>. This was derived from a pooled analysis of the <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> and <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a> trials. Aclidinium produced consistent improvements in both trough FEV1 (100 mL, P &lt; 0.0001) and peak FEV1 (172 mL, P &lt; 0.0001) from baseline to week 12 compared to placebo, which was in accordance with our findings. </p> <p>Other available evidence comes from <a href="./references#CD010509-bbs2-0069" title="KarabisA , LindnerL , MocarskiM , HuismanE , GreeningA . Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta‐analysis. International Journal of Chronic Obstructive Pulmonary Disease2013;8:405‐23. [PUBMED: 24043936] ">Karabis 2013</a>, which analysed the comparative efficacy of aclidinium versus glycopyrronium and tiotropium using network meta‐analysis. Twenty‐one studies were included, with three studies on aclidinium (<a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a>; <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a>). The authors concluded that aclidinium was comparable to tiotropium and glycopyrronium regarding trough FEV1 and TDI score improvement. For the SGRQ score, aclidinium resulted in a larger improvement than tiotropium 5 µg but comparable improvement to tiotropium 18 µg and glycopyrronium. The quality of the evidence for these conclusions, which were based on indirect comparison by network meta‐analysis through statistical inference, is questionable. We also determined that improvements in trough FEV1 with aclidinium were not statistically different from tiotropium. However, no trials in our review directly compared aclidinium to tiotropium in terms of SGRQ or TDI score. </p> <p>In another review by <a href="./references#CD010509-bbs2-0083" title="Suppli UlrikC . Aclidinium bromide: clinical benefit in patients with moderate to severe COPD. The Open Respiratory Medicine Journal2012;6:150‐4. [PUBMED: 23264836] ">Suppli 2012</a>, 10 trials, both parallel‐group and cross‐over studies, were included after a systematic search. However, there was no meta‐analysis and the conclusions drawn were based solely on the individual trial reports for a particular outcome. Thus, we did not consider the conclusions from that review to be suitable for comparison with our findings. Similarly, the other published reviews (<a href="./references#CD010509-bbs2-0050" title="AlaghaK , BourdinA , TumminoC , ChanezP . An update on the efficacy and safety of aclidinium bromide in patients with COPD. Therapeutic Advances in Respiratory Disease2011;5(1):19‐28. [PUBMED: 20884687] ">Alagha 2011</a>; <a href="./references#CD010509-bbs2-0051" title="AlaghaK , PalotA , SofalviT , PahusL , GouitaaM , TumminoC , et al. Long‐acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Therapeutic Advances in Chronic Disease2014; Vol. 5, issue 2:85‐98. [PUBMED: 24587893] ">Alagha 2014</a>; <a href="./references#CD010509-bbs2-0074" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. [PUBMED: 23075544] ">Maltais 2012</a>; <a href="./references#CD010509-bbs2-0082" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. [PUBMED: 22003291] ">Sims 2011</a>; <a href="./references#CD010509-bbs2-0097" title="WoodsJA , NealyKL , BarronsRW . Aclidinium bromide: an alternative long‐acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. The Annals of Pharmacotherapy2013;47(7‐8):1017‐28. [PUBMED: 23737515] ">Woods 2013</a>) were descriptive without pooling of the data making their findings inappropriate for comparison. </p> <p><a href="./references#CD010509-bbs2-0015" title="D'UrzoA , RennardS , JonesP , RekedaL , GilEG , CaractaC . Exposure‐adjusted anticholinergic adverse events following long‐term treatment with aclidinium bromide in patients with COPD. Chest2013;144(4_Meeting abstracts):717A. ">D'Urzo 2013b</a> performed a pooled analysis of the anticholinergic adverse events from three trials. <a href="./references#CD010509-bbs2-0023" title="GelbA , D'UrzoA , TashkinD , ZhongX , GilEG , CaractaC . Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two 1‐year studies. Chest2012;142(4_Meeting abstracts):691A. GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety and efficacy of twice‐daily aclidinium bromide in patients with COPD. Respiratory Medicine2013;107(12):1957‐65. GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40 (Suppl 56):376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year Study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185 (Meeting Abstracts):A2256. NCT01044459 . Long‐term safety, tolerability and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐35). http://www.clinicaltrials.gov/ct2/show/study/NCT01044459 (accessed 1 May 2014). TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40 (Suppl 56):528s [P2893]. ">Gelb 2013</a> and <a href="./references#CD010509-bbs2-0013" title="D'UrzoA , KerwinE , DonohueJ , RennardS , GelbA , LakkisH , et al. Effects of twice‐daily aclidinium bromide in COPD patients: A long‐term extension of ACCORD‐COPD I [Abstract]. European Respiratory Society Annual Congress, Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2890]. D'UrzoA , KerwinE , RennardS , HeT , Garcia GilE , CaractaC . Improvements in lung function with twice‐daily aclidinium bromide: results of a long‐term, phase 3 trial in patients with chronic obstructive pulmonary disease [Abstract]. Chest2012;142(4_Meeting abstracts):740A. D'UrzoA , KerwinE , RennardS , HeT , Garcia GilE , CaractaC . One‐year extension study of ACCORD COPD I: safety and efficacy of two doses of twice‐daily aclidinium bromide in patients with COPD. COPD2013;10(4):500‐10. [PUBMED: 23679347] D'UrzoA , KerwinEM , DonohueJF , RennardSI , GelbAF , LakkisH . Long‐term extension study of ACCORD COPD I: effects of two doses of twice‐daily aclidinium bromide in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2913. GelbA , D'UrzoA , TashkinD , ZhongX , GilEG , CaractaC . Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two one‐year studies. Chest2012;142(4_Meeting abstracts):691A. NCT00970268 . Long‐term extension study of the safety, tolerability, and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐36). http://www.clinicaltrials.gov/ct2/show/study/NCT00970268 (accessed 1 May 2014). ">D'Urzo 2013</a> had a duration of 52 weeks and the open label continuation phase of <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> was for 40 weeks. The highest incidence rates of adverse events with long‐term aclidinium therapy were urinary tract infections (2.9%), oropharyngeal pain (1.8%) and constipation (1.5%). Our review also demonstrated that the anticholinergic adverse events associated with aclidinium were similar to those associated with placebo or tiotropium. </p> <p>The major concern with the prolonged use of inhaled aclidinium bromide, a long‐acting anticholinergic, is the possible cardiovascular risk. In our analysis cardiac events were not increased with aclidinium compared to placebo, and were even non‐significantly fewer with aclidinium than with tiotropium. <a href="./references#CD010509-bbs2-0017" title="DonohueJ , TashkinD , FergusonG , KoweyP , RekedaL , ShresthaP , et al. Long‐term cardiovascular safety of aclidinium bromide in patients with COPD. Chest2013;144(4_Meeting abstracts):716A. ">Donohue 2013</a> analysed the major adverse cardiovascular events (MACE) with aclidinium 400 µg of cardiovascular (CV) death, non‐fatal myocardial infarction (MI) and non‐fatal stroke by pooling the results of two double‐blind trials with a duration of 52 weeks (<a href="./references#CD010509-bbs2-0013" title="D'UrzoA , KerwinE , DonohueJ , RennardS , GelbA , LakkisH , et al. Effects of twice‐daily aclidinium bromide in COPD patients: A long‐term extension of ACCORD‐COPD I [Abstract]. European Respiratory Society Annual Congress, Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2890]. D'UrzoA , KerwinE , RennardS , HeT , Garcia GilE , CaractaC . Improvements in lung function with twice‐daily aclidinium bromide: results of a long‐term, phase 3 trial in patients with chronic obstructive pulmonary disease [Abstract]. Chest2012;142(4_Meeting abstracts):740A. D'UrzoA , KerwinE , RennardS , HeT , Garcia GilE , CaractaC . One‐year extension study of ACCORD COPD I: safety and efficacy of two doses of twice‐daily aclidinium bromide in patients with COPD. COPD2013;10(4):500‐10. [PUBMED: 23679347] D'UrzoA , KerwinEM , DonohueJF , RennardSI , GelbAF , LakkisH . Long‐term extension study of ACCORD COPD I: effects of two doses of twice‐daily aclidinium bromide in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2913. GelbA , D'UrzoA , TashkinD , ZhongX , GilEG , CaractaC . Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two one‐year studies. Chest2012;142(4_Meeting abstracts):691A. NCT00970268 . Long‐term extension study of the safety, tolerability, and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐36). http://www.clinicaltrials.gov/ct2/show/study/NCT00970268 (accessed 1 May 2014). ">D'Urzo 2013</a>; <a href="./references#CD010509-bbs2-0023" title="GelbA , D'UrzoA , TashkinD , ZhongX , GilEG , CaractaC . Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two 1‐year studies. Chest2012;142(4_Meeting abstracts):691A. GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety and efficacy of twice‐daily aclidinium bromide in patients with COPD. Respiratory Medicine2013;107(12):1957‐65. GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40 (Suppl 56):376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year Study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185 (Meeting Abstracts):A2256. NCT01044459 . Long‐term safety, tolerability and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐35). http://www.clinicaltrials.gov/ct2/show/study/NCT01044459 (accessed 1 May 2014). TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40 (Suppl 56):528s [P2893]. ">Gelb 2013</a>) and one open label study over 40 weeks (the continuation phase of <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> or LAS‐MD‐38 part B). The MACE composite scores with aclidinium for double‐blind and open label studies were low (1.4% and 1.6% respectively). Similarly, <a href="./references#CD010509-bbs2-0020" title="FergusonG , KerwinE , SinghD , KoweyP , RekedaL , ShresthaP , et al. Cardiovascular safety of aclidinium bromide in COPD: pooled results from three placebo‐controlled studies. Chest2013;144(4_Meeting abstracts):715A. ">Ferguson 2013</a> pooled the CV events from <a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a>; <a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> and <a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a> trials and reported that the MACE composite scores were equal for aclidinium and placebo (0.3%). A double‐blind, randomised, placebo‐controlled parallel‐group phase IV trial (<a href="./references#CD010509-bbs2-0049" title="NCT01966107 . Evaluate the effect of aclidinium bromide on long‐term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). http://clinicaltrials.gov/ct2/show/NCT01966107 (accessed 1 May 2014). ">ASCENT COPD</a>) that is ongoing is assessing the cardiovascular safety of long‐term aclidinium therapy and is scheduled to be completed by January 2018. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010509-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010509-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010509-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score." data-id="CD010509-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.10 Number of patients with hospital admissions due to COPD exacerbation." data-id="CD010509-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.10 Number of patients with hospital admissions due to COPD exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.13 Non‐fatal serious adverse events." data-id="CD010509-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.13 Non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.2 Number of patients with exacerbations requiring steroids, antibiotics or both." data-id="CD010509-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Aclidinium bromide versus placebo, outcome: 1.2 Number of patients with exacerbations requiring steroids, antibiotics or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 1 Total number of deaths." data-id="CD010509-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 1 Total number of deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 2 Number of patients with exacerbations requiring steroids, antibiotics or both." data-id="CD010509-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 2 Number of patients with exacerbations requiring steroids, antibiotics or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 3 Quality of life: change from baseline in SGRQ total score." data-id="CD010509-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 3 Quality of life: change from baseline in SGRQ total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score." data-id="CD010509-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 5 Lung function: Change from baseline in trough FEV1 (L)." data-id="CD010509-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 5 Lung function: Change from baseline in trough FEV1 (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 6 Lung function: Change from baseline in peak FEV1 (L)." data-id="CD010509-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 6 Lung function: Change from baseline in peak FEV1 (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 7 Lung function: Change from baseline in normalised FEV1 AUC 0‐12 hour." data-id="CD010509-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 7 Lung function: Change from baseline in normalised FEV1 AUC 0‐12 hour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 8 Lung function: Change from baseline in trough FVC (L)." data-id="CD010509-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 8 Lung function: Change from baseline in trough FVC (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 9 Lung function: Change from baseline in peak FVC (L)." data-id="CD010509-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 9 Lung function: Change from baseline in peak FVC (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 10 Number of patients with hospital admissions due to COPD exacerbation." data-id="CD010509-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 10 Number of patients with hospital admissions due to COPD exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 11 Improvement in symptoms: Change from baseline in TDI focal score." data-id="CD010509-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 11 Improvement in symptoms: Change from baseline in TDI focal score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 12 Number of patients who achieved ≥ 1 unit improvement in TDI focal score." data-id="CD010509-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 12 Number of patients who achieved ≥ 1 unit improvement in TDI focal score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-13.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 13 Non‐fatal serious adverse events." data-id="CD010509-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 13 Non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 14 Withdrawals due to lack of efficacy." data-id="CD010509-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 14 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aclidinium bromide versus placebo, Outcome 15 Withdrawals due to adverse events." data-id="CD010509-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Aclidinium bromide versus placebo, Outcome 15 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 1 Total number of deaths." data-id="CD010509-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 1 Total number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 2 Number of patients with exacerbations requiring steroids, antibiotics or both." data-id="CD010509-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 2 Number of patients with exacerbations requiring steroids, antibiotics or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 3 Lung function: Change from baseline in trough FEV1 (L)." data-id="CD010509-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 3 Lung function: Change from baseline in trough FEV1 (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 4 Lung function: Change from baseline in peak FEV1 (L)." data-id="CD010509-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 4 Lung function: Change from baseline in peak FEV1 (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 5 Lung function: Change from baseline in trough FVC (L)." data-id="CD010509-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 5 Lung function: Change from baseline in trough FVC (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 6 Lung function: Change from baseline in peak FVC (L)." data-id="CD010509-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 6 Lung function: Change from baseline in peak FVC (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 7 Number of patients with hospital admissions due to COPD exacerbation." data-id="CD010509-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 7 Number of patients with hospital admissions due to COPD exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 8 Non‐fatal serious adverse events." data-id="CD010509-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 8 Non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 9 Withdrawals due to lack of efficacy." data-id="CD010509-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 9 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 10 Withdrawals due to adverse events." data-id="CD010509-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Aclidinium bromide versus long‐acting muscarinic antagonist, Outcome 10 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 1 Cardiac events." data-id="CD010509-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 1 Cardiac events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 2 Dry mouth." data-id="CD010509-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 2 Dry mouth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 3 Constipation." data-id="CD010509-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 3 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 4 Cerebrovascular events." data-id="CD010509-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 4 Cerebrovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 5 Diarrhoea." data-id="CD010509-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 5 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 6 Nasopharyngitis." data-id="CD010509-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 6 Nasopharyngitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 7 Headache." data-id="CD010509-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 7 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 8 Cough." data-id="CD010509-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 8 Cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 9 Hypertension." data-id="CD010509-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 9 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 10 Respiratory tract infections." data-id="CD010509-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 10 Respiratory tract infections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 11 Urinary tract infections." data-id="CD010509-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 11 Urinary tract infections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 12 Fatigue." data-id="CD010509-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 12 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 13 Dizziness." data-id="CD010509-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 13 Dizziness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 14 Dyspnoea." data-id="CD010509-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 14 Dyspnoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 15 Arthralgia." data-id="CD010509-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 15 Arthralgia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 16 Back pain." data-id="CD010509-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 16 Back pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010509-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/urn:x-wiley:14651858:media:CD010509:CD010509-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_t/tCD010509-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 17 Oropharyngeal pain." data-id="CD010509-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 17 Oropharyngeal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/media/CDSR/CD010509/image_n/nCD010509-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010509-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with stable chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> aclidinium bromide<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Aclidinium bromide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause)</b> <br/> Follow‐up: 6‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (2 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b> <br/> (0.43 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5252<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids, antibiotics or both</b> <br/> Follow‐up: 4‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b> <br/> (105 to 141) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.88</b> <br/> (0.74 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5624<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> <br/> Number of patients who achieved at least 4 units improvement in SGRQ total score<br/> Follow‐up: 12‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>396 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>494 per 1000</b> <br/> (462 to 527) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.49</b> <br/> (1.31 to 1.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4420<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life (SGRQ total score change from baseline) in the intervention groups was 2.34 lower (3.18 to 1.51 lower); (4442 participants; 7 studies) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional capacity</b> <br/> Six‐minute walking distance </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study assessed functional capacity</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations</b> <br/> Follow‐up: 4‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (17 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.64</b> <br/> (0.46 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5624<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b> <br/> Follow‐up: 4‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (40 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> <br/> (0.7 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5651<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> ‐2 for imprecision: the CI includes the possibility of both appreciable benefit and harm.<br/> <sup>2</sup><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> failed to report some outcomes of lung function in the published full text but it is unlikely to affect this outcome.<br/> <sup>3</sup><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> is double blinded for aclidinium and placebo arms though it is open label for tiotropium arm with no study limitation for this comparison.<br/> <sup>4</sup> ‐1 for imprecision: the CI includes important benefit and potential harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aclidinium bromide compared to placebo for stable chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010509-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with stable chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> aclidinium bromide<br/> <b>Comparison:</b> tiotropium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Tiotropium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Aclidinium bromide </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329<br/> (1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids, antibiotics or both</b> <br/> Follow‐up: 4‐6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (0 to 26)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.64</b> <br/> (0.31 to 22.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> <br/> St George's Respiratory Questionnaire (SGRQ) score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies measured and reported quality of life for aclidinium and tiotropium</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional capacity</b> <br/> Six‐minute walk distance </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies measured and reported functional capacity for aclidinium and tiotropium</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations</b> <br/> Follow‐up: 4‐6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> <br/> (0 to 18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b> <br/> (0.07 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b> <br/> Follow‐up: 4‐6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (3 to 46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.67</b> <br/> (0.17 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The corresponding risk for aclidinium bromide was calculated using the risk difference to avoid having zero in both columns. </p> <p><sup>2</sup> ‐1 for high risk of bias in <a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> because it was open label for tiotropium arm.<br/> <sup>3</sup><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> failed to report some outcomes of lung function in the published full text but it is unlikely to affect this outcome.<br/> <sup>4</sup> ‐2 for imprecision: the CI includes the possibility of both appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Aclidinium bromide compared to tiotropium for stable chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010509-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severity of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of aclidinium</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of aclidinium</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0001" title="EUCTR2005‐005101‐39‐AT . A 52‐week randomised, double‐blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2005‐005101‐39 (accessed 1 May 2014). JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPW , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64 Suppl IV:A168 [P213]. JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014). ">ACCLAIM/COPD I</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0002" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. [PUBMED: 21518460] NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014). RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM/COPD II</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0003" title="D'UrzoA , MakeBJ , KerwinEM , RekedaL , SanzMT , CaractaC , et al. Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1614. D’UrzoA , MakeB , KerwinE , RekedaL , Garcia GilE , CaractaC , et al. ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38 (55):729s [P3998]. GelbA , DonohueJ , D’UrzoA , RekedaL , Garcia GilE , LateinerJ . ACCORD COPD I: Twice‐daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam2011;38(55):149s [P876]. GelbAF , DonohueJF , D'UrzoA , RekedaL , JarretaD , LateinerJ . Improvements in quality of life and dyspnea in COPD patients with twice‐daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1616. KerwinE , D'UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18‐22; Barcelona. 2010:[P1235]. KerwinE , D’UrzoA , GelbA , LakkisH , Garcia GilE , CaractaC . Efficacy and safety of twice‐daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest2010;138(4):469A. KerwinE , RennardS , GelbA , RekedaL , Garcia GilE , CaractaC . ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice‐daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873]. KerwinEM , D'UrzoAD , GelbAF , LakkisH , Garcia GilE , CaractaCF . Efficacy and safety of a 12‐week treatment with twice‐daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD2012;9(2):90‐101. [PUBMED: 22320148] KerwinEM , RennardSI , GelbAF , RekedaL , Garcia GilE , CaractaC . Twice‐daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1592. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014). ">ACCORD COPD I</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200, 400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0004" title="NCT01045161 . To assess the long‐term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate‐to‐severe chronic obstructive pulmonary disease (COPD) (LAS‐MD‐38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014). RennardSI , ScanlonPD , FergusonGT , RekedaL , MaurerBT , Garcia GilE , et al. ACCORD COPD II: A randomised clinical trial to evaluate the 12‐week efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation2013;33(12):893‐904. ">ACCORD COPD II</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200, 400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0005" title="EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐001524‐38 (accessed 1 May 2014). NCT01462942 . Long‐term efficacy and safety of aclidinium/formoterol fixed‐dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014). SinghD , JonesP , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145:375A. ">ACLIFORM</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0006" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005]. EUCTR2009‐011600‐27‐CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐011600‐27. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health‐care utilisation and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24‐282011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting abstracts):A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. [PUBMED: 22441743] NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014). SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. ATTAIN: Twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66 Suppl 4:A171 [P255]. ">ATTAIN</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200, 400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0007" title="D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145:426A. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014). ">AUGMENT COPD</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0008" title="BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate‐to‐severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4253. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax2012;67 Suppl 2:A26 [S51]. BeierJ , KirstenAM , MrozR , SegarraR , ChuecosF , CaractaC , et al. Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4276. BeierJ , KirstenAM , MruzR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate‐to‐severe chronic obstructive pulmonary disease: results from a six‐week, randomised, controlled phase IIIb study. COPD2013;10(4):511‐22. [PUBMED: 23819698] BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185]. BeierJ , KirstenAM , MrózR , SegarraR , ChuecosF , CaractaC , et al. Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7‐11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184]. EUCTR2011‐000834‐12‐DE . A multiple dose, double‐blind, double‐dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 µg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2011‐000834‐12 (accessed 1 May 2014). NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014). ">Beier 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0009" title="ChanezP , BurgePS , DahlR , CreemersJ , ChuchalinA , LamarcaR , et al. Aclidinium bromide provides long‐acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics2010;23(1):15‐21. [PUBMED: 19683590] ChanezP , BurgeS , DahlR , CreemersJ , LamarcaR , GarciaGE . Once‐daily administration of aclidinium bromide, a novel, long‐acting anticholinergic: a phase II, dose‐finding study [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:[A286]. CharezP , BurgeS , CreemersJ , LamarcaR , GarciaGE . Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4‐8; Berlin. 2008:[2736]. ">Chanez 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(ATS)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25, 50, 100, 200,</p> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0010" title="CasaburiR , MaltaisF , CelliB , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[5558]. CelliB , MaltaisF , CasaburiR , PorszaszJ , Garcia GilE , CaractaC . Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1183]. MaltaisF , CelliB , CasaburiR , PorszaszJ , JarretaD , SeoaneB , et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine2011;105(4):580‐7. [PUBMED: 21183326] MaltaisF , CelliB , PorszaszJ , CasaburiR , GarciaGE , CaractaC . Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4428. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014). ">Maltais 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0011" title="NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014). ">NCT01572792</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> <p>(GOLD)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010509-bbs2-0012" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2007‐004435‐30 (accessed 1 May 2014). SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 µg in combination with formoterol in patients with COPD [Abstract]. Thorax2010;65 Suppl 4:P137. ">Sliwinski 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate to severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 µg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Once daily</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/full#CD010509-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010509-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aclidinium bromide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.43, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.46, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of patients with exacerbations requiring steroids, antibiotics or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: change from baseline in SGRQ total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.34 [‐3.18, ‐1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.96 [‐3.47, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.51 [‐3.50, ‐1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life: Number of patients who achieved ≥ 4 units improvement in SGRQ total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.31, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.08, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.32, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Lung function: Change from baseline in trough FEV1 (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.08, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.09, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Lung function: Change from baseline in peak FEV1 (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.15, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.15, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Lung function: Change from baseline in normalised FEV1 AUC 0‐12 hour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.10, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.08, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.10, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Lung function: Change from baseline in trough FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.14, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.10, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.14, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Lung function: Change from baseline in peak FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.23, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.23, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.22, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of patients with hospital admissions due to COPD exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.35, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Improvement in symptoms: Change from baseline in TDI focal score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.50, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.46, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.33, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number of patients who achieved ≥ 1 unit improvement in TDI focal score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.52, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.39, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.47, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.23, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.20, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.20, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.57, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Aclidinium once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Aclidinium twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aclidinium bromide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010509-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aclidinium bromide versus long‐acting muscarinic antagonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of patients with exacerbations requiring steroids, antibiotics or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.31, 22.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lung function: Change from baseline in trough FEV1 (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Lung function: Change from baseline in peak FEV1 (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Lung function: Change from baseline in trough FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Lung function: Change from baseline in peak FVC (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of patients with hospital admissions due to COPD exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.07, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.17, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.26, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aclidinium bromide versus long‐acting muscarinic antagonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010509-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiac events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.06, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.55, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.13, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.59, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.11, 68.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cerebrovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.25, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.11, 68.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.96, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 vs placebo once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.14, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 vs placebo twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.63, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Nasopharyngitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.95, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.50, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.98, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.33, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.78, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.07, 27.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Respiratory tract infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.77, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [0.14, 46.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Urinary tract infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.05, 20.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.31, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 vs tiotropium bromide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.06, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.44, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Arthralgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.98, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Back pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.74, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Oropharyngeal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.66, 1.64]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010509.pub2/references#CD010509-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010509.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010509-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010509-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010509-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010509-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010509-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010509\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010509\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010509\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010509\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010509\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010509.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010509.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010509.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010509.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010509.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713925309"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010509.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713925313"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010509.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d62248b69937a',t:'MTc0MDcxMzkyNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 